10 - sleuro.org · SYMPOSIUM 13.30-14.30 14.30-16.15 SLE and clinical trials: past and future Traditional synthetic drugs in SLE SLE genetics 16.15-16.45 16.45-18.30 Targets in SLE

1

VENICE20165-8 October Palazzo del Casinò

10EUROPEAN LUPUS M E E T I N G

th

Final Program

2

“When I seek another word for ‘music’,

I never find any other word than ‘Venice’".

Friedrich Nietzsche

3

“When I seek another word for ‘music’,

I never find any other word than ‘Venice’".

Friedrich Nietzsche

ContentsWelcome message p. 4

Committees p. 5

Program overview p. 6

Scientific program Wednesday, October 5 p. 8Thursday, October 6 p. 9Friday, October 7 p. 21Saturday, October 8 p. 33

Poster sessions p. 39

Scientific information Abstract book p. 65Guidelines for chairpersons and speakers p. 65Guidelines for oral communications and poster display p. 65E-Posters and discussion p. 66Poster discussion p. 67Best papers p. 67CME Accreditation p. 67

Social networks p. 68

General informationCongress Venue p. 70Useful information p. 70Registration information p. 74

Sponsored session p. 78

Authors index p. 79

Acknowledgements and industry support p. 88

4

Welcome Message

Dear Colleagues

We are pleased to welcome you to the 10th European Lupus Meeting in the beautiful view of Venice!We have gone through more than 12 months of passionate preparations for the forthcoming days in order to offer all participants the chance to share ideas, knowledge and projects on SLE.

The Meeting will entail a number of lectures and symposia devoted to different aspects of pathogenesis and management of SLE and associated comorbidities and conditions. Many different topics will be discussed, with a special focus on controversial issues regarding therapeutic strategies and outcomes that we yearn for.

Plenty of specialists from all over the world are awaited and more than 300 abstract and 46 late-breaking abstracts were received which will be discussed in oral and poster sessions. Posters presenting the most innovative and interesting data will be selected for electronic presentation (e-Posters).

Beside traditional sessions, pre-course preceding the plain congress will satisfy anybody curious of basic immunology and descending therapeutic options and morning breakfast with professors will provide an additional chance of discussion with the "lupus veterans".

The 10th European Lupus Meeting will put together and merge different competencies and novelties, so that at the end we hope all participants will feel confident “lupologists”.We wish all of you to enjoy the Lupus Meeting, and the lovely city of Venice.

Sincerely,

Prof. Andrea Doria, Prof. Angela Tincani

Follow us on Facebook and Twitter #10LupusMeeting

5

CommitteesCONGRESS CHAIRPERSONSA. Doria (Chair), Padova (IT) A. Tincani (Co-Chair), Brescia (IT)

CONGRESS PRE-COURSE CHAIRPERSONP. Sarzi-Puttini, Milano (IT)

HONORARY CHAIRPERSONL. Punzi, Padova (IT)

PAST CHAIRSD. Boumpas, Athens (GR) S. Bombardieri, Pisa (IT)R. Cervera, Barcelona (ES)D. Isenberg, London (UK)J. Kalden, Erlangen (DE)C. Kallenberg, Amsterdam (NL)M. Khamashta, London (UK)H.M. Moutsopoulos, Athens (GR)J. Smolen, Vienna (AT) C. Vasconcelos, Porto (PT)

LOCAL SCIENTIFIC COMMITTEEG. Ferraccioli, Roma (IT)M. Galeazzi, Siena (IT)M. Govoni, Ferrara (IT)A. Mathieu, Cagliari (IT)P.L. Meroni, Milano (IT)M. Mosca, Pisa (IT) G. Moroni Milano (IT)R. Perricone, Roma (IT)P. Sarzi-Puttini, Milano (IT) G. Valesini, Roma (IT)

SCIENTIFIC SECRETARIATL. Andreoli, Brescia (IT)L. Iaccarino, Padova (IT)C. Tani, Pisa (IT)

INTERNATIONAL SCIENTIFIC COMMITTEEN. Agmon-Levin, Tel-Hashomer (IL)M.E. Alarcón-Riquelme, Granada (ES)Z. Amoura, Paris (FR) M. Aringer, Dresden (DE) L. Arnaud, Strasbourg (FR)J.H.M. Berden, Nijmegen (NL)G. Bertsias, Crete (GR)D. Boumpas, Athens (GR)I. Bruce, Manchester (UK) J. Calvo-Alén, Torrelavega (ES)R. Cervera, Barcelona (ES)C. Chizzolini, Geneva (CH)N. Costedoat-Chalumeau, Paris (FR)D. D'Cruz, London (UK)T. Dörner, Berlin (DE)R. Fischer-Betz, Düsseldorf (DE)R. Furie, Great Neck (US)M.E. Gershwin, Davis (US)F. Hiepe, Berlin (DE)F. Houssiau, Leuven (BE)D. Isenberg, London (UK)S. Jacobsen, Copenhagen (DK)D. Jayne, Cambridge (UK)M. Khamashta, London (UK)A. Kuhn, Mainz (DE)X. Mariette, Paris (FR)E. Morand, Clayton (AU)J. M. Pego-Reigosa, Vigo (ES)M. Petri, Baltimore (US)B. Pons-Estel, Rosario (AR)L. Rönnblom, Uppsala (SE)G. Ruiz-Irastorza, Barakaldo (ES)M. Schneider, Düsseldorf (DE)Y. Shoenfeld, Tel-Hashomer (IL)M. Tektonidou, Athens (GR)G. Tsokos, Boston (US)M. Urowitz, Toronto (CA)R. Van Vollenhoven, Amsterdam (NL)C. Vasconcelos, Porto (PT)R. Voll, Freiburg (DE)T. Vyse, London (UK)X. Zeng, Beijing (CN)

6

Program OverviewWEDNESDAY 5 OCTOBER, 2016

hrs PERLA ROOM CASINO' ROOM PARTY ROOM

11.00

18.30-20.00 OPENING CEREMONY

20.00-21.00 Welcome Cocktail

Opening Registrations and Exhibition

LEGEND:

PARELLEL SESSIONS PLENARY LECTURES

BREAKFAST MEETING INDUTRY SPONSORED SESSION

THURSDAY 6 OCTOBER, 2016


08.00-09.00 Controversial cases:discussion with the experts

Controversial cases: discussion with the experts

09.00-10.30 Belimumab, rituximab and other targeted therapy

Hormones and environments in SLE

Microparticles and biomarkers in lupus nephritis

10.30-11.00

11.00-12.30 Targeting B cell in SLE Redefining lupus B cells and plasma cells in lupus nephritis

12.30-13.30 INDUSTRY-SPONSORED SYMPOSIUM

13.30-14.30

14.30-16.15 SLE and clinical trials: past and future

Traditional synthetic drugs in SLE SLE genetics

16.15-16.45

16.45-18.30 Targets in SLE treatment Lupus nephritis: definition and outcomes Cell death and lupus

Lunch and E-Poster Discussion

Coffee break and Poster Discussion


7

FRIDAY 7 OCTOBER, 2016


08.00-09.00 How to publish in an international journal

Controversial cases: discussion with the experts

09.00-10.30 B and T cells in lupus Damage and comorbidities Targeting B cells and plasmacells in SLE

10.30-11.00

11.00-12.30 SLE registries and cohorts (1)

Neuropsychiatric lupus and antithrombotic therapy

SLE activity, damage and prevention

12.30-13.00 Role of IFN alpha in SLE

13.00-13.30 The relevance of costimulation in SLE

13.30-14.30

14.30-16.15 SLE registries and cohorts (2) APS and SLE Neonatal lupus and other pregnancies related concerns

16.15-16.45

16.45-18.30 Lupus pregnancy Joint and skin in SLE Outcome, costs and comorbidities in SLE

Program Overview

LEGEND:

PARELLEL SESSIONS PLENARY LECTURES

BREAKFAST MEETING INDUTRY SPONSORED SESSION

SATURDAY 8 OCTOBER, 2016


09.00-10.30 Challenges in the management of APS

Old and new clinical and pathogenetic challenges

in SLE

Early lupus and overlap autoimmune diseases

10.30-11.00 Coffee break

11.00-12.30 Biomarkers and risk stratification in lupus Improving outcome in SLE Lupus animal models and

new pathogenetic clues

12.30 CLOSING CEREMONY

Lunch and E-Poster Discussion



8

Scientific ProgramWEDNESDAY 5 OCTOBER, 2016

Perla Room

18:30-20:00 OPENING CEREMONY

18:30-18:55 WELCOME FROM THE CONGRESS CHAIRPERSONS A. Doria (Padova, Italy), A. Tincani (Brescia, Italy)

18:55-19:15 APS & SLE: THE CHALLENGES OF 2020 G. Hughes (London, UK)

19:15-19:35 LUPUS, HPV, AND THE MICROBIOME: AFTER ALL EVERYTHING IS INFECTIOUS UNTIL PROVEN OTHERWISE Y. Shoenfeld (Tel-Hashomer, Israel)

19:35-19:40 PRESENTATION OF THE 12TH INTERNATIONAL CONGRESS ON SLE E. Morand (Clayton, Australia)

19:40-19:45 PRESENTATION OF THE 11TH EUROPEAN LUPUS MEETING M. Schneider (Düsseldorf, Germany)

19:45-20:00 CONCLUSIONS A. Doria (Padova, Italy)

9

Scientific ProgramTHURSDAY 6 OCTOBER, 2016

Casinò Room

08:00-09:00 BREAKFAST MEETING “Controversial cases: discussion with the experts” Difficult cases of lupus glomerulonephritis: discussion with the experts I. Boletis (Athens, Greece), G. Moroni (Milano, Italy)

Party Room

08:00-09:00 BREAKFAST MEETING “Controversial cases: discussion with the experts” Difficult cases of lupus glomerulonephritis: discussion with the experts L. Iaccarino (Padova, Italy), M. Urowitz (Toronto, Canada)

Perla Room

09:00-10:30 BELIMUMAB, RITUXIMAB AND OTHER TARGETED THERAPY Chairs: S. Bombardieri (Pisa, Italy), E. Morand (Clayton, Australia)09:00-09:25 When to use belimumab in clinical practice setting A. Doria (Padova, Italy)09:25-09:50 Combining rituximab and belimumab in SLE and Sjögren syndrome X. Mariette (Paris, France)

09:50-10:00 ANIFROLUMAB, AN ANTI-INTERFERON-ALPHA RECEPTOR MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) R. Furie1, J.T. Merrill2, V.P. Werth3, M. Khamashta4, K. Kalunian5, P. Brohawn6, G. Illei6, J. Drappa6, L. Wang6, S. Yoo7 (1Great Neck, USA, 2Oklahoma City, USA, 3Philadelphia, USA, 4London, UK, 5La Jolla, USA, 6Gaithersburg, USA, 7Rockville, USA)10:00-10:10 ANIFROLUMAB REDUCES DISEASE ACTIVITY IN MULTIPLE ORGAN DOMAINS IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) J.T. Merrill1, R. Furie2, V.P. Werth3, M. Khamashta4, J. Drappa5, L. Wang5, G. Illei5

(1Oklahoma City, USA, 2Great Neck, USA, 3Philadelphia, USA, 4London, UK, 5Gaithersburg, USA)10:10-10:20 CONTINOUS REGENERATION OF LONGLIVED MEMORY PLASMA CELLS IN MURINE SLE REQUIRES A COMBINED DEPLETION OF PLASMA CELLS AND THEIR PRECURSORS B. Hoyer, A. Taddeo, L. Khodadadi, Q. Cheng, A. Radbruch, F. Hiepe (Berlin, Germany)10:20-10:30 RITUXIMAB FOR SLE REFRACTORY TO CONVENTIONAL TREATMENT: RESULTS OF A COHORT EVALUATING EFFICACY AND LONG-TERM OUTCOME C. Staveri, S.N. Liossis (Patras, Greece)

10

Scientific ProgramCasinò Room

09:00-10:30 HORMONES AND ENVIRONMENTS IN SLE Chairs: A. Gabrielli (Ancona, Italy), M.E. Gershwin (Davis, USA)09:00-09:25 Effects from the neuroendocrine immune network in SLE M. Cutolo (Genova, Italy)09:25-09:50 The environmental basis of autoimmunity M.E. Gershwin (Davis, USA)

09:50-10:00 ALL DISEASE BEGINS IN THE GUT: CELIAC DISEASE CO-EXISTENCE WITH SLE S. Dahan, Y. Shoenfeld, H. Amital, D. Ben Ami (Tel-Hashomer, Israel)10:00-10:10 HELMINTHES RELATED TUFTSIN-PHOSPHORYLCHOLINE COMPOUND: SUCCESSFUL TREATMENT OF MURINE LUPUS NEPHRITIS AND ITS EFFECT ON THE MICROBIOTA Y. Shoenfeld1, M. Blank1, T. Bashi1, H. Neuman2, O. Givol1, A. Volkov1, I. Barshack1, M. Fridkin3, O. Koren2

(1Ramat Gan, Israel, 2Sefat, Israel, 3Rehovot, Israel)10:10-10:20 SERUM ANTI-MÜLLERIAN HORMONE LEVELS IN SLE PATIENTS: INFLUENCE OF DISEASE SEVERITY AND THERAPY ON THE OVARIAN RESERVE C. Di Mario, L. Petricca, M.R. Gigante, G. Marino, V. Varriano, A. Paglionico, A. Barini, S. Canestri, A. Barini, B. Tolusso, P. Cattani, G. Ferraccioli, E. Gremese (Roma, Italy)10:20-10:30 DIAGNOSING ADRENAL INSUFFICIENCY IN RENAL PATIENTS TREATED WITH LONG-TERM CORTICOSTEROIDS USING SHORT SYNACTHEN TESTS M. Al-Shaghana, P. Hewins, S. Logan (Birmingham, UK)

11

Scientific ProgramParty Room

09:00-10:30 MICROPARTICLES AND BIOMARKERS IN LUPUS NEPHRITIS Chairs: J.H.M. Berden (Nijmegen, The Netherlands), R. Perricone (Roma, Italy)09:00-09:25 Microparticles - a culprit in the pathogenesis of SLE? S. Jacobsen (Copenhagen, Denmark)09:25-09:50 The role of CSF-1 and BAFF in lupus nephritis A. Schwarting (Mainz, Germany)

09:50-10:00 ENDOTHELIAL PROGENITOR CELLS AND ENDOTHELIAL MICROPARTICLES IN ANTIPHOSPHOLIPID SYNDROME: A NEW PARADIGM OF ENDOTHELIAL DAMAGE C. Barbati, F.R. Spinelli, F. Conti, F. Miranda, F. Ceccarelli, M. Vomero, G. Valesini, C. Alessandri (Roma, Italy) 10:00-10:10 THE ROLE OF OSTEOPONTIN AS A CANDIDATE BIOMARKER OF RENAL INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS C. Garufi, F.R. Spinelli, S. Truglia, F. Ceccarelli, F. Miranda, V. Pacucci, C. Alessandri, G. Valesini, F. Conti (Roma, Italy)10:10-10:20 BIOMARKERS IN LUPUS NEPHRITIS: POSSIBLE ROLE OF SERUM CYSTATIN-C, SERUM BETA2-MICROGLOBULIN, URINARY ALPHA1 - MICROGLOBULIN AND ALBUMIN/CREATININ RATIO (ACR) L. Petricca, C. Di Mario, F. Forni, B. Tolusso, M.R. Gigante, G. Marino, V. Varriano, A. Paglionico, L. Messuti, P. Cattani, G. Ferraccioli, E. Gremese (Roma, Italy)10:20-10:30 THE ROLE OF INNATE IMMUNITY IN THE PATHOGENESIS OF LUPUS NEPHRITIS: FOCUS ON INTERLEUKIN 32 S. Truglia1, C. Alessandri1, F. Ciccia2, A. Rizzo2, T. Colasanti1, F. Miranda1, F.R. Spinelli1, F. Ceccarelli1, G. Triolo2, A. Capozzi1, M. Sorice1, G. Valesini1, F. Conti1 (1Roma, Italy, 2Palermo, Italy)

10.30-11.00 COFFEE BREAK AND POSTER DISCUSSION (See page n. 69)

12

Scientific ProgramPerla Room

11:00-12:30 TARGETED THERAPY IN SLE Chairs: T. Dörner (Berlin, Germany), X. Mariette (Paris, France)11:00-11:25 Lesson learned from using rituximab to treat lupus over 15 years D. Isenberg (London, UK)11:25-11:50 Targeting B cells in lupus nephritis D. Jayne (Cambridge, UK)

11:50-12:00 ANTI-PENTRAXIN3 (PTX3) ANTIBODIES ARISING FOLLOWING IMMUNIZATION WITH PTX3 IMPROVE SURVIVAL AND DELAY LUPUS-LIKE GLOMERULONEPHRITIS IN NZB/NZWF1 MICE M. Gatto, A. Ghirardello, R. Luisetto, M. Fedrigo, M. Beggio, L. Iaccarino, L. Punzi, A. Doria (Padova, Italy) 12:00-12:10 IL-2 THERAPY REDUCES INTRARENAL TCON HYPERACTIVITY AND RENAL INFLAMMATION IN NZB/W MICE WITH ACTIVE LUPUS NEPHRITIS A. Rose1, C. Von Spee-Mayer1, P. Enghard1, K. Wu1, A. Kuehl1, L. Kloke1, A. Radbruch1, G.R. Burmester1, J.Y. Humrich2, G. Riemekasten2 (1Berlin, Germany, 2Lübeck, Germany)12:10-12:20 SURVIVAL RATE AND CAUSES OF WITHDRAWAL OF BELIMUMAB IN SLE IN A REAL LIFE SETTING F. Morello, F.R. Spinelli, F. Ceccarelli, L. Massaro, C. Alessandri, G. Valesini, F. Conti (Roma, Italy)12:20-12:30 THERAPEUTIC APPLICATION OF HUMAN UMBILICAL CORD WHARTON JELLY-DERIVED MESENCHYMAL STEM CELLS (HUCMS) IN SYSTEMIC LUPUS ERYTHEMATOSUS: PITFALLS AND PERSPECTIVES A. Alunno, O. Bistoni, P. Montanucci, G. Basta, T. Pescara, I. Pennoni, R. Calafiore, R. Gerli (Perugia, Italy)

13


11:00-12:30 REDEFINING LUPUS Chairs: D. D’Cruz (London, UK), J. Kalden (Erlangen, Germany)11:00-11:25 New SLE criteria - aims, concepts, methods M. Aringer (Dresden, Germany)11:25-11:50 When lupus starts. When lupus is detected J. Calvo-Alén (Torrelavega, Spain)

11:50-12:00 LUPUS IN THE COMMUNITY VERSUS REFERRAL CENTRES: DISEASE PHENOTYPE AND SEVERITY AND IMPLICATIONS FOR CLINICAL CARE AND RHEUMATOLOGY TRAINING A. Fanouriakis1, I. Gergianaki2, C. Adamichou2, P. Sidiropoulos2, T. Karageorgas1, P. Katsibri1, G. Spyrou2, G. Bertsias2, D. Boumpas1,2 (1Athens, Greece, 2Heraklion, Greece)12:00-12:10 MULTIPARAMETRIC DETECTION OF AUTOANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) ENABLES DEFINITION OF SLE PATIENT SUBGROUPS P. Budde1, H.D. Zucht1, H. Göhler1, P. Rengers1, K. Marquart1, S. Vordenbäumen2, P. Schulz-Knappe1, M. Schneider2 (1Dortmund, Germany, 2Düsseldorf, Germany)12:10-12:20 COMPARISON OF BRITISH ISLES LUPUS ASSESMENT GROUP (BILAG) -2004 AND CLASSIC BILAG INDICES S. Tosounidou1, C.S. Yee2, V. Farewell3, C. Gordon1

(1Birmingham, UK, 2Doncaster, UK, 3Cambridge, UK)12:20-12:30 MULTIPLE AUTOIMMUNE SYNDROME DOES NOT PROTECT FROM SEVERE ORGAN INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS - A CLINICAL, IMMUNOLOGICAL AND GENETIC ANALYSIS M. Fidalgo, R. Faria, C. Carvalho, D. Mendonca, G. Carvalheiras, B. Martins da Silva, C. Vasconcelos (Porto, Portugal)

14


11:00-12:30 B CELLS AND PLASMA CELLS IN LUPUS NEPHRITIS Chairs: R. Giacomelli (L'Aquila, Italy), F. Hiepe (Berlin, Germany)11:00-11:25 A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells exists in health but is defective in SLE C. Mauri (London, UK)11:25-11:50 Plasma cells in nephritic kidneys - key players in lupus pathogenesis R. Voll (Freiburg, Germany)

11:50-12:00 A UNIQUE B CELL PHENOTYPE IDENTIFIED IN AFRICAN AMERICAN LUPUS PATIENTS L. Menard1, S. Habte1, W. Gonsiorek1, D. Lee1, D. Banas1, D. Holloway1, N. Manjarez-Orduno1, M. Cunningham1, D. Stetsko1, F. Casano1, S. Kansal1, J. Carman1, C. Zhang1, F. Abidi2, R. Furie2, S. Nadler1, S. Suchard1 (1Princeton, USA, 2Great Neck, USA)12:00-12:10 EFFECT OF B LYMPHOCYTE STIMULATOR AND ITS INHIBITION ON ENDOTHELIAL PROGENIT CELLS AND MATURE ENDOTHELAL CELLS F.R. Spinelli, C. Barbati, L. Massaro, F. Morello, F. Ceccarelli, T. Colasanti, C. Alessandri, G. Valesini, F. Conti (Roma, Italy)12:10-12:20 EFFECT OF SERPINB3 TREATMENT ON THE DEVELOPMENT OF GLOMERULONEPHRITIS IN NZB/NZW F1 MICE A. Ghirardello, R. Luisetto, M. Beggio, M. Gatto, F. Saccon, P. Pontisso, L. Punzi, A. Doria (Padova, Italy)12:20-12:30 SLEDAI-2K AND POLYARTHRITIS ARE THE BEST PREDICTORS OF RESPONSE TO BELIMUMAB IN PATIENTS WITH ACTIVE SLE IN CLINICAL PRACTICE SETTING: DATA FROM MULTICENTRIC ITALIAN STUDY S. Bettio1, L. Iaccarino1, R. Reggia2, G. Emmi3, F. Ceccarelli4, T. Ubiali5, A. Bortoluzzi6, G. De Marchi7, E. Bartoloni Bocci8, L. Andreoli2, M. Zen1, L. Emmi3, F. Conti4, M. Gerosa5, P.L. Meroni5, M. Govoni6, S. De Vita7, R. Gerli8, A. Tincani2, A. Doria1 (1Padova, Italy, 2Brescia, Italy, 3Firenze, Italy, 4Roma, Italy, 5Milano, Italy, 6Ferrara, Italy, 7Udine, Italy, 8Perugia, Italy)

Perla Room

12.30-13.30 INDUSTRY SPONSORED SESSION

Level 2

13.30-14.30 LUNCH AND E-POSTER DISCUSSION (See page n. 68)

15


14:30-16:15 SLE AND CLINICAL TRIALS: PAST AND FUTURE Chairs: J. Smolen (Vienna, Austria), R. Van Vollenhoven (Amsterdam, The Netherlands)14:30-14:55 Lesson learned from lupus clinical trials R. Furie (Great Neck, USA)14:55-15:20 Evidence that development of new biologics for lupus can succeed J.T. Merrill (Oklahoma City, USA)15:20-15:45 Why will lupus nephritis trials not fail anymore? F. Houssiau (Leuven, Belgium)

15:45-15:55 ONSET AND DURABILITY OF EFFICACY OF BELIMUMAB ADMINISTERED SUBCUTANEOUSLY PLUS STANDARD OF CARE MEDICATIONS TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN A PHASE III TRIAL A. Doria1, W. Stohl2, A. Schwarting3, A. Hammer4, N.L. Fox5, J. Groark6, D. Bass6, B. Pobiner4, L. Edwards4, W. Eastman4, D. Gordon6 (1Padova, Italy, 2Los Angeles, USA, 3Bad Kreuznach, Germany, 4Triangle Park, USA, 5Maryland, USA, 6Philadelphia, USA)15:55-16:05 PHASE I STUDY OF IMMU-115 (HUMANIZED ANTI-CD74 ANTIBODY) TARGETING ANTIGEN PRESENTING CELLS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) D.J. Wallace1, W.A. Wegener2, H. Horne2, D.M. Goldenberg2 (1Los Angeles, USA, 2Morris Plains, USA)16:05-16:15 LOW-DOSE IL-2 THERAPY IN SLE: RESULTS FROM A COMBINED PHASE I/IIA CLINICAL TRIAL J. Humrich1, C. Von Spee-Mayer2, E. Siegert2, M. Bertolo2, A. Rose2, D. Abdirama2, P. Enghard2, F. Hiepe2, A. Radbruch2, G.R. Burmester2, G. Riemekasten1 (1Lübeck, Germany, 2Berlin, Germany)

16


14:30-16:15 TRADITIONAL SYNTHETIC DRUGS IN SLE Chairs: I. Bruce (Manchester, UK), H.M. Moutsopoulos (Athens, Greece)14:30-14:55 Tacrolimus as adjunctive therapy in lupus nephritis: a review of the evidence D. D’Cruz (London, UK)14:55-15:20 Mycophenolic area under the curve is associated with high risk of SLE nephritis relapse Z. Amoura (Paris, France)15:20-15:45 Impact of hydroxychloroquine in pregnancy outcome of patients with SLE and APS M. Cuadrado (London, UK)

15:45-15:55 RESPONSE TO A COMBINED HYDROXYCHLOROQUINE-QUINACRINE TREATMENT IN SLE WITH CUTANEOUS AND/OR JOINT DISEASE S. Porta1, A. Martinez1, A. Ugarte1, R. Ríos2, N. Ortego2, G. Ruiz-Irastorza1 (1Barakaldo, Spain, 2Granada, Spain)15:55-16:05 SURVIVAL OF PREDNISONE-FREE REMISSION IN SLE PATIENTS WITH SEROLOGICALLY ACTIVE CLINICAL QUIESCENT DISEASE L. Nalotto, F. Ometto, L. Iaccarino, M. Zen, S. Bettio, M. Gatto, A. Ghirardello, M. Larosa, A. Doria (Padova, Italy)16:05-16:15 AURION STUDY: 12 WEEK DATA OF MULTI-TARGET THERAPY WITH VOCLOSPORIN, MMF AND STEROIDS FOR LUPUS NEPHRITIS R. Yahya3, A.H. Abdul Gafor3, T.M. Chan2, R. Huizinga1, N. Solomons1 (1Victoria, Canada, 2Hong Kong, Hong Kong, 3Kuala Lumpur, Malaysia)

17


14:30-16:15 SLE GENETICS Chairs: M. Galeazzi (Siena, Italy), T. Vyse (London, UK)14:30-14:45 SLE Genetics in different populations - comparisons and implications T. Vyse (London, UK)14:45-15:20 Towards a -OMIC Reclassification of systemic autoimmune disease M.E. Alarcón-Riquelme (Malaga, Spain)15:20-15:45 Transcriptomic analysis for human SLE: lessons learned and future directions D. Boumpas (Athens, Greece)

15:45-15:55 A POLYMORPHISM UPSTREAM MIR1279 GENE IS ASSOCIATED WITH PERICARDITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS AND CONTRIBUTES TO DEFINITION OF A GENETIC RISK MODEL PROFILE C. Perricone, C. Ciccacci, F. Ceccarelli, E. Cipriano, S. Rufini, C. Politi, A. Latini, C. Alessandri, F.R. Spinelli, G. Novelli, G. Valesini, P. Borgiani, F. Conti (Roma, Italy)15:55-16:05 ALLELE-SPECIFIC BINDING DIFFERENCES OF FOX TRANSCRIPTION FACTORS TO IKZF3 RISK ALLELES IN SYSTEMIC LUPUS ERYTHEMATOSUS D. Cunninghame Graham, A. Cortini, C. Odhams, T. Vyse (London, UK)16:05-16:15 SINGLE CELL GENE EXPRESSION STUDIES IN LUPUS PATIENT MONOCYTES REVEAL NOVEL PATTERNS REFLECTING DISEASE ACTIVITY, INTERFERON, AND MEDICAL TREATMENT T. Niewold, Z. Jin, W. Fan, M. Jensen, J. Dorschner, D. Vsetecka, S. Amin, A. Makol, F. Ernste, T. Osborn, K. Moder, V. Chowdhary (Rochester, USA)


18


16:45-18:30 TARGETS IN SLE TREATMENT Chairs: A. Doria (Padova, Italy), M. Urowitz (Toronto, Canada)16:45-17:10 Treating to target, treating to remission in SLE: strategies for the future R. Van Vollenhoven (Amsterdam, The Netherlands)17:10-17:35 Low disease activity in SLE - towards validation and application of a new endpoint E. Morand (Clayton, Australia)17:35-18:00 PRO in SLE, pros and cons M. Schneider (Düsseldorf, Germany)

18:00-18:10 THE PREDICTIVE EFFECT OF A RANGE OF DURATION OF REMISSION ON DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS. RESULTS FROM A PROSPECTIVE MONOCENTRIC COHORT OF 293 PATIENTS. M. Zen, F. Saccon, S. Bettio, L. Nalotto, M. Gatto, M. Larosa, L. Iaccarino, A. Doria (Padova, Italy)18:10-18:20 A COMPLETE REMISSION LASTING AT LEAST ONE YEAR INFLUENCES THE OUTCOME IN PATIENTS AFFECTED BY SLE: RESULTS FROM A LARGE MONOCENTRIC COHORT F. Ceccarelli, E. Cipriano, I. Leccese, L. Massaro, F. Miranda, F. Morello, V. Pacucci, C. Perricone, V. Orefice, M. Pendolino, F.R. Spinelli, S. Truglia, C. Alessandri, G. Valesini, F. Conti (Roma, Italy)18:20-18:30 HOW FREQUENT IS LOW DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS? REAL LIFE DATA FROM A MONOCENTRIC COHORT OF CAUCASIAN PATIENTS. R. Vagelli, C. Tani, L. Carli, C. Stagnaro, S. Vagnani, M. Mosca (Pisa, Italy)

19


16:45-18:30 LUPUS NEPHRITIS: DEFINITION AND OUTCOMES Chairs: D. Jayne (Cambridge, UK), R.A. Sinico (Milano, Italy)16:45-17:10 What is the added value of renal biopsy and rebiopsy to clinical data in lupus nephritis? G. Moroni (Milano, Italy)17:10-17:35 Outcomes in lupus nephritis: the evolving concept of ESRD M. Tektonidou (Athens, Greece)17:35-18:00 Interstitial nephritis: a different outcome? G. Ferraccioli (Roma, Italy)

18:00-18:10 ANTIPHOSPHOLIPID ANTIBODIES IN LUPUS NEPHRITIS I. Parodis, L. Arnaud, J. Gerhardsson, A. Zickert, B. Sundelin Von Feilitzen, V. Malmström, E. Svenungsson, I. Gunnarsson (Stockholm, Sweden)18:10-18:20 INTERSTITIAL INFLAMMATORY INFILTRATE AT RENAL BIOPSY AND OUTCOMES OF CLASS IV LUPUS NEPHRITIS V. Varriano, A. Paglionico, E. Gremese, S. Costanzi, L. Petricca, M. Nowik, M.R. Gigante, G. Marino, L. Messuti, G. Ferraccioli (Roma, Italy)18:20-18:30 ACCELERATED ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS - A MATTER OF RENAL INVOLVEMENT E. Svenungsson1, J. Gustafsson1, M. Herlitz Lindberg1, I. Gunnarsson1, S. Pettersson1, K. Elvin1, J. Öhrvik1, A Larsson2, K. Jensen-Urstad1

(1Stockholm, Sweden, 2Uppsala, Sweden)

20


16:45-18:30 CELL DEATH AND LUPUS Chairs: C. Chizzolini (Geneva, Switzerland), S. Jacobsen (Copenhagen, Denmark)16:45-17:10 Mechanisms of cell death in the pathogenesis of SLE G. Valesini (Roma, Italy)17:10-17:35 Apoptosis induced modifications of nucleosomal auto-antigens are targeted in SLE J.H.M. Berden (Nijmegen, The Netherlands)17:35-18:00 Crescentic lupus nephritis: challenges and pitfalls I. Boletis (Athens, Greece)

18:00-18:10 INDUCTION OF APOPTOSIS AND AUTOPHAGY IN CIRCULATING PBMC BY MICROPARTICLES FROM PATIENTS WITH SYSTEMIC LUPUS ERYTEMATOSUS F. Miranda, C. Barbati, C. Alessandri, F.R. Spinelli, F. Ceccarelli, S. Truglia, G. Valesini, F. Conti (Roma, Italy)18:10-18:20 DEFECTIVE CLEARANCE OF PHAGOCYTIC SUBSTRATES IN SLE AND OTHER SYSTEMIC AUTOIMMUNE DISEASES REFLECT INCREASED NETS GENERATION A.A. Manfredi, G.A. Ramirez, M. Baldini, E. Baldissera, E.P. Bozzolo, M.G. Sabbadini, P. Rovere-Querini, N. Maugeri (Milano, Italy)18:20-18:30 AUTOPHAGY-MEDIATED RELEASE OF TISSUE FACTOR AND IL-17 ON NEUTROPHIL EXTRACELLULAR TRAPS PROMOTES KIDNEY INJURY IN SYSTEMIC LUPUS ERYTHEMATOSUS E. Frangou1,2, A. Chrysanthopoulou3, K. Kambas3, E. Apostolidou3, G. Bertsias4, P. Verginis1, C. Gakiopoulou1, K. Ritis3, D. Boumpas1 (1Athens, Greece, 2Nicosia, Cyprus, 3Alexandroupolis, Greece, 4Heraklion, Greece)

21

Scientific ProgramFRIDAY 7 OCTOBER, 2016

Casinò Room

08:00-09:00 HOW TO PUBLISH IN AN INTERNATIONAL JOURNAL M.E. Gershwin (Davis, USA)

Party Room

08:00-09:00 BREAKFAST MEETING “Controversial cases: discussion with the experts “ Difficult cases of lupus glomerulonephritis: discussion with the experts C. Perricone (Rome, Italy), Y. Shoenfeld (Tel-Hashomer, Israel)

Perla Room

09:00-10:30 B AND T CELLS IN LUPUS Chairs: D. Isenberg (London, UK), C. Kallenberg (Amsterdam, The Netherlands)09:00-09:25 B lineage cell disturbances in SLE driving autoimmunity T. Dörner (Berlin, Germany)09:25-09:50 Targeted drug delivery in the treatment of lupus G. Tsokos (Boston, USA)

09:50-10:00 IGM ANTIBODIES AGAINST PHOSPHORYLCHOLINE PROMOTE T REGULATORY CELL POLARIZATION IN SLE AND ATHEROSCLEROSIS J. Frostegård, A. Liu, J. Sun (Stockholm, Sweden)10:00-10:10 IL-10 PRODUCING CCR6+T-CELLS ARE A DISTINCT POPULATION OF B-HELPER T-CELLS THAT PLAY A PATHOGENIC ROLE IN SYSTEMIC LUPUS ERYTHEMATOSUS P. Larghi1, F. Facciotti1, N. Gagliani2, A. Penatti1, M. Paroni1, B. Haringer1,3, I. Kastirr1.3, Y. Kobayashi2, A. Iseppon2, M. Moro1, M.C. Crosti1, M. Bombaci1, K. Stolzel3, S. Torretta1, L. Pignataro1, F. Ingegnoli1, S. Abrignani1, P.L. Meroni1, R.A. Flavell2.3, J. Geginat1 (1Milano, Italy, 2New Haven, USA, 3Berlin, Germany)10:10-10:20 BANK1 INTERACTS WITH TRAF6 AND MYD88 IN INNATE IMMUNE SIGNALING OF B CELLS I. Georg, A. Díaz Barreiro, N. Varela Hernández, M. Morell Hita, M.E. Alarcón-Riquelme (Granada, Spain)10:20-10:30 IN VITRO INDUCED REGULATORY T-CELLS CAN REDUCE SEVERITY OF LUPUS ARTHRITIS B. Jacobs, H. Leiss, I. Gessl, B. Niederreiter, A. Puchner, C.W. Steiner, J. Smolen, G.H. Stummvoll (Vienna, Austria)

22


09:00-10:30 DAMAGE AND COMORBIDITIES Chairs: A. Mathieu (Cagliari, Italy), B. Pons-Estel (Rosario, Argentina) 09:00-09:25 Update on damage accrual in SLE I. Bruce (Manchester, UK)09:25-09:50 Evolving concept of SLE comorbidities: heart & bone M. Urowitz (Toronto, Canada)

09:50-10:00 COMORBIDITIES IN SOUTH AFRICANS WITH SYSTEMIC LUPUS ERYTHEMATOSUS L. Greenstein, K. Makan, M. Tikly (Johannesburg, South Africa) 10:00-10:10 RISK OF ORGAN DAMAGE AND MORTALITY IN SLE PATIENTS FULFILLING THE ACR OR THE SLICC CLASSIFICATION CRITERIA: A 10-YEAR, PROSPECTIVE INCEPTION COHORT STUDY L. Sousa Ines, M. Rodrigues, D. Jesus, J.A.P. Da Silva (Coimbra, Portugal)10:10-10:20 IMPACT OF HIV INFECTION ON THE COURSE OF SYSTEMIC LUPUS ERYTHEMATOSUS M. Tikly, H. Ngandu-Ntumba, A. Mvudi (Johannesburg, South Africa)10:20-10:30 VASCULAR AGE, CALCULATED BY PULSE WAVE VELOCITY, IS GREATER THAN CHRONOLOGICAL AGE IN PATIENTS WITH SYSTEMIC LUPUS ERITHEMATOSUS: A MONOCENTRIC CROSS-SECTIONAL STUDY C. Tani, R.M. Bruno, L. Carli, S. Armenia, R. Vagelli, M. Di Pilla, R. Gherardini, S. Taddei, L. Ghiadoni, M. Mosca (Pisa, Italy)

23

Party Room

09:00-10:30 TARGETING B CELLS AND PLASMACELLS IN SLE Chairs: E. Toubi (Haifa, Israel), R. Voll (Freiburg, Germany)09:00-09:25 The challenge of plasma cell targeting in lupus F. Hiepe (Berlin, Germany)09:25-09:50 Long-term observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment D. Roccatello (Torino, Italy)09:50-10:00 PROTEASOME INHIBITION WITH BORTEZOMIB IN SLE PROMOTES THERAPEUTICALLY RELEVANT DEPLETION OF SHORT- AND LONG- LIVED PLASMA CELLS BUT DOES NOT PREVENT THEIR REGENERATION T. Alexander, Q. Cheng, J. Klotsche, B.F. Hoyer, A. Taddeo, R. Bisen, G.R. Burmester, A. Radbruch, F. Hiepe (Berlin, Germany)10:00-10:10 GLYCOGEN SYNTHASE KINASE-3 IS HYPERPHOSPHORYLATED IN SLE AND PROVIDES A FEEDBACK MECHANISM FOR THE GENERATION OF REGULATORY B CELLS A. Clarke1, A. Harin1, S. Masters1, B. Rhodes3, T. Vyse2, K. Simon1 (1Oxford, UK, 2London, UK, 3Birmingham, UK)10:10-10:20 SUPPORT FOR PHOSPHOINOSITOL 3 KINASE INHIBITORS AS TREATMENT OF LUPUS USING IN SILICO DRUG REPURPOSING ANALYSIS D. Toro-Dominguez1, P. Carmona-Sáez1, M.E. Alarcón-Riquelme1,2

(1Granada, Spain, 2Stockholm, Sweden)10:20-10:30 THE INCREASE OF CIRCULATING CD4+ T-CELLS WITH EFFECTOR PHENOTYPE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS MAY BE REVERTED AFTER BELIMUMAB THERAPY S. Piantoni1, M. Scarsi1.2, L. Andreoli1, F. Dall’Ara1, A. Zanola1, A. Tincani1, P. Airò1

(1Brescia, Italy, 2Esine, Italy)


Scientific Program

24

Perla Room

11:00-12:30 SLE REGISTRIES AND COHORTS (1) Chairs: D. Boumpas (Athens, Greece), M. Schneider (Düsseldorf, Germany)11:00-11:25 Update on the Hopkins lupus cohort: from serologies to treatment to outcomes M. Petri (Baltimore, USA)11:25-11:50 RELESSER (Registry of SLE patients of the Spanish Society of Rheumatology): objectives, current achievements... and a look at the future J.M. Pego-Reigosa (Vigo, Spain)

11:50-12:00 BASELINE CHARACTERISTICS AND RISK FACTORS OF SLE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: A MULTI-CENTER STUDY IN CHINA J. Qian1, M. Li1, Q. Wang1, J. Zhao1, Z. Tian1, W. Wei2, X. Zhang3, X. Zuo4, M. Zhang5, P. Zhu6, S. Ye7, W. Zhang7, Y. Zheng1, W. Qi2, Y. Li8, Z. Zhang1, F. Ding9, J. Gu3, X. Zeng1 (1Beijing, China, 2Tianjin, China, 3Guangzhou, China, 4Changsha, China, 5Nanjing, China, 6Xi’an, China, 7Shanghai, China, 8Harbin, China,9Jinan, China)12:00-12:10 ADULT OUTCOMES IN A LARGE COHORT OF CHILDHOOD-ONSET SLE PATIENTS: FERTILITY AND PREGNANCIES – THE CHILL-NL STUDY N. Groot1, W. van Dijk1, R.J.E.M. Dolhain1, M. Bijl2, E.J. Zirkzee1, Y.K.O. Teng3, K. de Leeuw2, I.E.M. Bultink4, R. Fritsch-Stork5, S.S.M. Kamphuis1 (1Rotterdam, The Netherlands, 2Groningen, The Netherlands, 3Leiden, The Netherlands, 4Amsterdam, The Netherlands, 5Utrecht, The Netherlands)12:10-12:20 THE ITALIAN SLE SURVEY BY WEB: INVESTIGATING PATIENTS’ UNMET NEEDS AND IMPROVING CARE SYSTEM THROUGH VIABLE ONLINE SURVEY TOOLS M. Falanga, C. Metallo, A. Canzona (Roma, Italy)12:20-12:30 PURE RED CELL APLASIA IN PATIENTS FROM SLE REGISTRY FROM THE SPANISH SOCIETY OF RHEUMATOLOGY (RELESSER) A. Lois-Iglesias1, I. Rúa-Figueroa2, C. Erausquin2, D. Grados3, A. Olivé3, V. Quevedo4, J. Alegre5, J. Calvo-Alén6, F.J. López-Longo7, M. Galindo7, F.J. de Toro1, C. Mouriño8, J.M. Pego-Reigosa8 (1Coruña, Spain, 2Gran Canaria, Spain, 3Badalona, Spain, 4Monforte, Spain, 5Valencia, Spain, 6Sierrallana, Spain, 7Madrid, Spain, 8Vigo, Spain)

Scientific Program

25

Casinò Room

11:00-12:30 NEUROPSYCHIATRIC LUPUS AND ANTITHROMBOTIC THERAPY Chairs: G. Ruiz-Irastorza (Barakaldo, Spain), G. Valesini (Rome, Italy)11:00-11:25 Neuropsychiatric lupus: attribution and diagnosis. Limitations and opportunities M. Govoni (Ferrara, Italy)11:25-11:50 Controversies: shall we recommend acetylsalicylic acid for the primary prevention of thrombosis in patients with aPL? L. Arnaud (Strasbourg, France)

11:50-12:00 ELEVATED INTERFERON-ALPHA CAUSES CEREBRAL MICROVASCULAR DISEASE: A MODEL FOR NEUROLUPUS? D. Hunt1, I. Campbell2, S. McGlasson1, A. Jury1, A. Jackson1 (1Edinburgh, UK, 2Sydney, Australia)12:00-12:10 NEUROPSYCHIATRIC MANIFESTATIONS IN PEDIATRIC-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: EXPERIENCE OF A SPANISH TERTIARY CENTER W. Sifuentes Giraldo, A.L. Boteanu, S. Garrote Corral, M.L. Gámir Gámir, A. Zea Mendoza (Madrid, Spain)12:10-12:20 EVIDENCE OF ALTERED BLOOD BRAIN BARRIER PERMEABILITY IN SYSTEMIC LUPUS ERYTHEMATOSUS USING MAGNETIC RESONANCE IMAGING H. Brunner (Cincinnati, USA)12:20-12:30 ANTICOAGULATION AND LONGTERM OUTCOMES IN PATIENTS WITH RENAL ARTERY STENOSIS AND ANTIPHOSPHOLIPID SYNDROME A. Casian1, S. Sangle1, S. Manoustathopoulou1, N. Jordan2, D D’Cruz1

(1London, UK, 2Cambridge, UK)

Scientific Program

26

Party Room

11:00-12:30 SLE ACTIVITY, DAMAGE AND PREVENTION Chairs: A. Afeltra (Roma, Italy), F. Houssiau (Bruxelles, Belgium) 11:00-11:25 Disease activity and damage in SLE: report from a large monocentric cohort F. Conti (Roma, Italy)11:25-11:50 The effect of long-term use of HCQ in patients with primary APS L. Andreoli (Brescia, Italy)

11:50-12:00 IMMUNE COMPLEXES CONTAINING SERUM B-CELL ACTIVATING FACTOR AND IMMUNOGLOBULIN G CORRELATE WITH DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS J. Friebus-Kardash1,2, L. Branco1, C. Ribi3,4, C. Chizzolini3, U. Huynh-Do5, D. Dubler1, A. Kribben2, U. Eisenberger2, M. Trendelenburg1

(1Basel, Switzerland, 2Essen, Germany, 3Geneva, Switzerland, 4Lausanne, Switzerland, 5Bern, Switzerland)12:00-12:10 AUTOIMMUNE HEMOLYTIC ANEMIA AND THROMBOCYTOPENIA IN A SINGLE CENTRE COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM TURKEY: CLINICAL ASSOCIATIONS AND EFFECT ON DISEASE DAMAGE AND SURVIVAL B. Artim Esen, S. Kamali, A. Gul, L. Ocal, M. Inanc (Istanbul, Turkey)12:10-12:20 CHRONIC DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS: EVOLUTION AFTER 5-YEAR FOLLOW-UP I. Leccese, F. Ceccarelli, L. Massaro, C. Perricone, E. Cipriano, F.R. Spinelli, C. Alessandri, G. Valesini, F. Conti (Roma, Italy)12:20-12:30 SLICC DAMAGE INDEX IS A PREDICTOR FOR HOSPITALIZATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: A 7-YEAR COHORT STUDY OF 297 PATIENTS FROM A TERTIARY REFERRAL CENTRE M. Rodrigues, D. Jesus, J.A.P. da Silva, L. Inês (Coimbra, Portugal)

Perla Room

12:30-13:00 ROLE OF IFN alpha IN SLE Chair: A. Doria (Padova, Italy) Speaker: R. Furie (Great Neck, USA)

Perla Room

13:00-13:30 THE RELEVANCE OF COSTIMULATION IN SLE Chair: A. Tincani (Brescia, Italy) Speaker: J.T. Merrill (Oklahoma City, USA)

Scientific Program

27

Level 2

13.30-14.30 LUNCH AND E-POSTER DISCUSSION (See page n. 68)

Perla Room

14:30-16:15 SLE REGISTRIES AND COHORTS (2) Chairs: M. Petri (Baltimore, USA), L. Punzi (Padova, Italy)14:30-14:55 The Swiss SLE cohort study: cardio-vascular risk and clinico-serological correlates C. Chizzolini (Geneva, Switzerland)14:55-15:20 5-year outcome of Chinese patients with SLE: data from CSTAR X. Zeng (Beijing, China)15:20-15:45 Ethnicity & socioeconomic status. Their impact on SLE outcome. B. Pons-Estel (Rosario-Santa Fe, Argentina)

15:45-15:55 CHRONOLOGICAL ANALYSIS OF DAMAGE ACCRUAL IN SLE PATIENTS FROM THE SPANISH REGISTRY (RELESSER) J.M. Pego-Reigosa1, A. Lois-Iglesias2, C. Mouriño1, F.J. López-Longo3, M. Galindo3, J. Calvo-Alén4, J. Uña1, V. Balboa1, A. Olivé5, T. Otón6, L. Horcada7, A. Sánchez7, C. Montilla7, R. Melero7, V. Martínez-Taboada7, E. Diez7, M. Fernández7, E. Ruiz7, J.H. Beriain7, I. Rúa-Figueroa8 (1Vigo, Spain, 2Coruña, Spain, 3Madrid, Spain, 4Sierrallana, Spain, 5Badalona, Spain, 6Torreón de Ardoz, Spain, 7Easer, Spain, 8Gran Canaria, Spain)15:55-16:05 ANTI-PHOSPHOLIPID ANTIBODY PREVALENCE AND CARDIOVASCULAR MORBIDITY IN THE GENERAL POPULATION OF THE CAMELIA STUDY C.F. Selmi, M. De Santis, E. Generali, P.M. Battezzati, A. Ceribelli, S.A. Lari, P.L. Meroni, M. Zuin (Milano, Italy)16:05-16:15 CAUSES OF MORTALITY AMONG FILIPINO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN A SINGLE TERTIARY HOSPITAL L. Salvador, M.F.J. Edar, S. Navarra (Manila, Philippines)

Scientific Program

28

Casinò Room

14:30-16:15 APS AND SLE Chairs: L. Arnaud (Strasbourg, France), V. Pengo (Padova, Italy)14:30-14:55 SLE and APS: differences and similarities P.L. Meroni (Milano, Italy)14:55-15:20 Novel aspects of non criteria of APS N. Agmon-Levin (Tel-Hashomer, Israel)15:20-15:45 Antiphospholipid related damage in SLE A. Tincani (Brescia, Italy)

15:45-15:55 PHOSPHATIDYLSERINE/PROTHROMBIN ANTIBODIES IN PREGNANT PATIENTS WITH SLE AND ANTIPHOSPHOLIPID SYNDROME P. Rovere-Querini1, V. Canti1, S. Del Rosso1, A. Hoxha2, L. Coletto1, G.A. Ramirez1, I. Vaglio Tessitore1, S. Rosa1, A.A. Manfredi1, M.T. Castiglioni1, A. Ruffatti2

(1Milano, Italy, 2Padova, Italy)

15:55-16:05 ANTIPHOSPHOLIPID ANTIBODIES AND LOW COMPLEMENT LEVELS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: ASSOCIATION WITH CLINICAL MANIFESTATIONS AND PROGNOSIS A Paglionico, V. Varriano, E. Gremese, L. Petricca, M.R. Gigante, G. Marino, G. Ferraccioli (Roma, Italy)16:05-16:15 RISK FACTORS FOR A THROMBOTIC EVENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID ANTIBODIES: A PROSPECTIVE 10-YEARS FOLLOW-UP STUDY S. Sciascia, A. Kuzenko, I. Castagno, M.T. Bertero (Torino, Italy)

Scientific Program

29

Party Room

14:30-16:15 NEONATAL LUPUS AND OTHER PREGNANCIES RELATED CONCERNS Chairs: J.P. Buyon (New York, USA), A. Ruffatti (Padova, Italy)14:30-14:55 Neonatal lupus: prognosis for mother and child N. Costedoat-Chalumeau (Paris, France)14:55-15:20 The pathogenesis of heart block and mechanism of action of hydroxychloroquine R. Clancy (New York, USA)15:20-15:45 Management of Anti-Ro/Ssa positive pregnant women: pros and cons of an intensive screening A.L. Brucato (Bergamo, Italy)

15:45-15:55 EFFICACY AND SAFETY OF MODIFIED-RELEASE PREDNISONE IN SYSTEMIC LUPUS ERYTHEMATOSUS PREGNANCIES M. Meroni1, V. Ramoni2,3, M. Limonta2, M. Cutolo1

(1Genova, Italy, 2Bergamo, Italy, 3Pavia, Italy, 4Bergamo, Italy)15:55-16:05 1ST TRIMESTER COMBINED SCREENING AND AUTOIMMUNE DISEASES: IMPACT OF PRE-ANALYTICAL VARIABLES ON RISK ASSESSMENT M. Sousa1, R. Ribeiro1, A. Syngelaki2, K. Nicolaides2

(1Lisbon, Portugal, 2London, UK)16:05-16:15 PREGNANCY AND FETAL OUTCOME IN SLE PATIENTS: THE IMPORTANCE OF DISEASE REMISSION BEFORE CONCEPTION M. Larosa1, N. Benzaquén2, M. Zen1, S. Bettio1, L. Nalotto1, M. Gatto1, L. Iaccarino1, A. Doria1

(1Padova, Italy, 2Córdoba, Argentina)


Scientific Program

30

Perla Room

16:45-18:30 LUPUS PREGNANCY Chairs: N. Costedoat-Chalumeau (Paris, France), A. Tincani (Brescia, Italy)16:45-17:10 Lupus and pregnancy: predictors of adverse pregnancy outcomes J.P. Buyon (New York, USA)17:10-17:35 Current strategies for family planning in SLE patients R. Fischer-Betz (Düsseldorf, Germany)17:35-18:00 Management of pregnant lupus patients with medications M. Ostensen (Trondheim, Norway)

18:00-18:10 IN VITRO FERTILIZATION IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS OR ANTIPHOSPHOLIPID SYNDROME: A SERIES OF 97 PROCEDURES P. Orquevaux1, A. Masseau2, V. Le Guern3, V. Gayet3, D. Vautier-Brouzes3, G. Guettrot-Imbert3, D. Le Thi Huong3, B. Wechsler3, N. Morel3, P. Cacoub3, J.L. Pennaforte1, J.C. Piette3, N. Costedoat-Chalumeau3 (1Reims, France, 2Nantes, France, 3Paris, France)18:10-18:20 COUNSELING ON FAMILY PLANNING AND CONTRACEPTION IN PATIENTS WITH RHEUMATIC DISEASES: ANALYSIS OF 324 PATIENT-REPORTED QUESTIONNAIRES FROM A MULTICENTER ITALIAN STUDY M. Lazzaroni1, F. Dall’Ara1, L. Andreoli1, M. Rodrigues2, R. Reggia1, E. Bartoloni Bocci3, C. Chighizola4, P. Conigliaro5, A. Corrado6, S. D’Angelo7, M. Favaro8, E. Generali4, M. Gerosa4, M. Meroni9,13, M. Padovan10, G. Pazzola11, S. Peccatori12, I. Prevete5, V. Ramoni13, 19, G.D. Sebastiani5, C. Tani14, M. Trevisani15, M. Vadacca5, E. Vivaldelli16, E. Visalli17, L. Zuliani18, A. Afeltra18, E. Baldissera4, A.L. Brucato13, F. Cantatore6, R. Caporali19, M. Cutolo9, A. Doria8, R. Foti17, A. Gabrielli18, R. Gerli3, M. Govoni10, A. Maier16, N. Malavolta17, P.L. Meroni4, G. Minisola5, C. Montecucco19, M. Mosca14, I. Olivieri7, G. Paolazzi12, R. Perricone5, N. Romeo20, A. Ruffatti8, C. Salvarani11, C.F. Selmi4, L. Sinigaglia4, A. Tincani1 (1Brescia, Italy, 2Coimbra, Portugal, 3Perugia, Italy, 4Milano, Italy, 5Roma, Italy, 6Foggia, Italy, 7Potenza Italy, 8Padova, Italy, 9Genova, Italy, 10Ferrara, Italy, 11Reggio Emilia, Italy, 12Trento, Italy, 13Bergamo, Italy, 14Pisa, Italy, 15Bologna, Italy, 16Bolzano, Italy, 17Catania, Italy, 18Ancona, Italy, 19Pavia, Italy, 20Cuneo, Italy)18:20-18:30 THE USE OF ANTIMALARIAL DRUGS DURING PREGNANCY CAN PREVENT THE DEVELOPMENT OF PREECLAMPSIA IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS M.A. Saavedra, D. Miranda-Hernández, A. Lara-Mejía, A. Sánchez, C. Cruz-Reyes, U. Ángeles, L.J. Jara (México City, Mexico)

Scientific Program

31

Casinò Room

16:45-18:30 JOINT AND SKIN IN SLE Chairs: S. Manzi (Pittsburgh, USA), S. Todesco (Padova, Italy) 16:45-17:10 Treatment of cutaneous lupus: from the bench to the bedside A. Kuhn (Mainz, Germany)17:10-17:35 Joint involvement in SLE M. Mosca (Pisa, Italy)17:35-18:00 Drug induced lupus A. Parodi (Genova, Italy)

18:00-18:10 PREDICTORS OF MUSCULOSKELETAL FLARES AND JACCOUD’S ARTHROPATHY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A 5-YEAR PROSPECTIVE STUDY M. Piga, A. Gabba, M. Congia, F. Figus, A. Cauli, A. Mathieu (Cagliari, Italy)18:10-18:20 PREVALENCE OF ANTI-CARBAMILATED PROTEINS ANTIBODIES IN A COHORT OF SLE PATIENTS WITH JOINT INVOLVEMENT L. Massaro, F. Ceccarelli, T. Colasanti, M. Pendolino, E. Cipriano, C. Perricone, F. Natalucci, G. Capalbo, F.R. Spinelli, C. Alessandri, G. Valesini, F. Conti (Roma, Italy)18:20-18:30 SAFETY PROFILE AND CAUSE OF DISCONTINUATION OF ANTIMALARIALS IN A MONOCENTRIC COHORT OF PATIENTS WITH SYSTEMIC AND DISCOID LUPUS ERYTHEMATOSUS E. Moscarelli, F.R. Spinelli, F. Ceccarelli, F. Miranda, S. Truglia, C. Perricone, C. Garufi, F. Morello, L. Massaro, C. Alessandri, G. Valesini, F. Conti (Roma, Italy)

Scientific Program

32

Party Room

16:45-18:30 OUTCOME, COSTS AND COMORBIDITIES IN SLE Chairs: Z. Amoura (Paris, France), M. Aringer (Dresden, Germany)16:45-17:10 Very long-term outcome in SLE C. Tani (Pisa, Italy)17:10-17:35 Epidemiology, clinical and financial burden of SLE in Greece G. Bertsias (Crete, Greece)17:35-18:00 SLE and central sensatization syndromes: a cross-sectional study P. Sarzi-Puttini (Milano, Italy)

18:00-18:10 OVERALL CAUSE AND CAUSE SPECIFIC MORTALITY IN A MULTINATIONAL INCEPTION COHORT OF SLE M. Urowitz (Toronto, Canada)18:10-18:20 DOES THE SLICC DAMAGE INDEX UNDERESTIMATE COMORBIDITY- ASSOCIATED IMPACT ON THE SURVIVAL OF ELDERLY SLE PATIENTS? A. Daniel, G. Eugénio, J.A. Pereira da Silva, L. Inês (Coimbra, Portugal)18:20-18:30 LONG-TERM OUTCOMES OF CHINESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A SINGLE-CENTER COHORT STUDY Z. Wang, M. Li, Y. Wang, X. Zeng (Beijing, China)

Scientific Program

33

SATURDAY 8 OCTOBER, 2016

Perla Room

09:00-10:30 CHALLENGES IN THE MANAGEMENT OF APS Chairs: P.L. Meroni (Milano, Italy), Y. Shoenfeld (Tel-Hashomer, Israel)09:00-09:25 Clinical and laboratory diagnosis of APS including the hot topic (the so - called Seronegative APS) M. Khamashta (London, UK)09:25-09:50 Catastrophic antiphospholipid syndrome: 25 years in the front page R. Cervera (Barcelona, Spain)

09:50-10:00 DIFFERENTIATION BETWEEN APS PATIENTS AND ANTIPHOSPHOLIPID ANTIBODY-POSITIVE CARRIERS – IMPOSSIBLE OR MATTER OF TECHNIQUE? D. Roggenbuck1, P. Schierack1, M. Mahler2, P. Marcor3, M.O. Borghi4, P.L. Meroni4 (1Senftenberg, Germany, 2San Diego, USA, 3Trieste, Italy, 4Milano, Italy)10:00-10:10 THROMBOSPONDIN-1 IS ELEVATED IN THE PLASMA OF PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME. IMPLICATIONS IN THE PATHOGENESIS OF ANTIPHISPHOLIPID SYNDROME. M. Patsouras, E. Grika, A. Tzioufas, P. Vlachoyiannopoulos (Athens, Greece)10:10-10:20 UTILITY OF ANTI-BETA2GLYCOPROTEIN I IGA AND ANTI-DOMAIN 1 AS A RISK FACTOR FOR RECURRENT THROMBOSIS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME C. Nalli1, M. Rodrigues2, L. Andreoli1, E. Balestrieri1, G.L. Norman3, M. Mahler3, A. Tincani1

(1Brescia, Italy, 2Coimbra, Portugal, 3San Diego, USA)10:20-10:30 ANTIPHOSPHATIDYLSERINE/PROTHROMBIN ANTIBODIES AS A RISK FACTOR OF DISEASE SEVERITY IN PRIMARY ANTIPHOSPHOLIPID SYNDROME A. Hoxha, E. Mattia, M. Tonello, L. Meneghel, E. Salvan, A. Banzato, V. Pengo, A. Ruffatti (Padova, Italy)

Scientific Program

34

Casinò Room

09:00-10:30 OLD AND NEW CLINICAL AND PATHOGENETIC CHALLENGES IN SLE Chairs: L. Lightstone (London, UK), C. Vasconcelos (Porto, Portugal)09:00-09:25 Targeting the type I interferon system in SLE L. Rönnblom (Uppsala, Sweden)09:25-09:50 Reducing the dose of glucocorticoids for severe lupus G. Ruiz-Irastorza (Barakaldo, Spain)

09:50-10:00 ADHERENCE TO HYDROXYCHLOROQUINE AS ASSESSED BY MEASUREMENTS OF DRUG AND METABOLITE BLOOD LEVELS IN AN INTERNATIONAL PROSPECTIVE STUDY OF SLE PATIENTS IN FLARE N. Costedoat-Chalumeau1, F. Houssiau2, P. Izmirly3, V. Le Guern1, S. Navarra4, M. Jolly3, G. Ruiz-Irastorza5, E. Hachulla1, N. Agmon-Levin6, Y. Shoenfeld6, F. Dall’Ara7, J. Buyon3, C. Deligny1, R. Cervera5, C. Pineau8, L. Galicier1, A. Tincani7, J.C. Piette1, M. Petri3, D. Isenberg9 (1Paris, France, 2Bruxelles, Belgium, 3New York, USA, 4Manila, Philippines, 5Barakaldo, Spain, 6Tel-Hashomer, Israel, 7Brescia, Italy, 8Montreal, Canada, 9London, UK)10:00-10:10 STUDY OF ANTI-APOLIPOPROTEIN A-I ANTIBODIES AND PARAOXONASE 1 ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS; CORRELATION WITH DISEASE ACTIVITY AND DAMAGE INDICES I. Algazzar, E. Elserougy, M. Ahmed, D. Habib, I. Fikry (Cairo, Egypt) 10:10-10:20 INTERFERON REGULATORY FACTOR 5 PROMOTES DISEASE IN THE FCGAMMARIIB-/- MOUSE MODEL OF LUPUS THROUGH TLR7- DEPENDENT AND -INDEPENDENT PATHWAYS H. Menn-Josephy, K. Yasuda, P. Shukla, A. Watkins, T. Aprahamian, T. Dhawan, G. Wilson, R. Bonegio, I. Rifkin (Boston, USA)10:20-10:30 INDUCTION OF TYPE-I INTERFERON MRNA IN HUMAN CD14+ CELLS TREATED WITH NEUTROPHIL EXTRACELLULAR TRAPS T. Bohgaki, S. Yasuda, M. Kato, K. Oku, O. Amengual, T. Horita, T. Atsumi (Sapporo, Japan)

Scientific Program

35

Party Room

09:00-10:30 EARLY LUPUS AND OVERLAP AUTOIMMUNE DISEASES Chairs: J. Calvo-Alén (Torrelavega, Spain), M. Li (Beijing, China)09:00-09:25 Early lupus project: clinical and autoantibody profile of patients with recent onset SLE at diagnosis and during follow-up G.D. Sebastiani (Roma, Italy)09:25-09:50 Relationship between SLE, other CTDs and celiac disease R. Gerli (Perugia, Italy)

09:50-10:00 SUBCLINICAL RETINAL INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS AND SJÖGREN SYNDROME PATIENTS P. Conigliaro, M. Cesareo, C. Canofari, G. Draghessi, P. Triggianese, C. Valeri, L. Novelli, G. Aloe, R. Perricone (Roma, Italy)10:00-10:10 INTERFERON-RELATED CHEMOKINE CXCL-10(IP-10) IN INCOMPLETE SYSTEMIC LUPUS ERYTHEMATOSUS; A POTENTIAL PREDICTIVE BIOMARKER FOR DISEASE PROGRESSION? W. Lambers, K. de Leeuw, M.F. Jonkman, H. Bootsma, J. Westra (Groningen, The Netherlands) 10:10-10:20 VALUE OF IGA ANTIPHOSPHOLIPID ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS AND UNEXPLAINED PREGNANCY MORBIDITY K. de Leeuw, C. Roozendaal, S. Gordijn, H. Bootsma (Groningen, The Netherlands)10:20-10:30 SEROLOGICAL EVOLUTION IN FERTILE WOMEN WITH POSITIVE ANTIPHOSPHOLIPID ANTIBODIES L. Riancho-Zarrabeitia, G. Daroca, M. López-Hoyos, P. Muñoz, A. Haya, M. González, R. Del Barrio, V. Martínez-Taboada (Santander, Spain)

10.30-11.00 COFFEE BREAK

Scientific Program

36

Perla Room

11:00-12:30 BIOMARKERS AND RISK STRATIFICATION IN LUPUS Chairs: J.M. Dayer (Geneva, Switzerland), A. Tincani (Brescia, Italy)11:00-11:25 Lupus biomarkers: prognosis, diagnosis and disease monitoring S. Manzi (Pittsburgh, USA)11:25-11:50 Novel approaches to define patients with lupus nephritis at high risk of poor outcomes L. Lightstone (London, UK)

11:50-12:00 SLE-KEY® ICHIP® PLATFORM IDENTIFIES A ‘LUPUS AUTOANTIBODIES SIGNATURE’ EARLY IN DISEASE WHICH PERSISTS INDEPENDENT OF DISEASE DURATION AND ACTIVITY C. Putterman1, P. Safer2, K. Jakobi2, R. Sorek2, I. Gilkaite2, S. Wallace3, A. Harris Altice3, D.S. Batty3, I.R. Cohen2

(1New York, USA, 2Rehovot, Israel, 3Richmond, USA) 12:00-12:10 DISCOVERY AND INITIAL VALIDATION OF AUTOANTIBODIES AGAINST THE MAJOR VAULT PROTEIN (MVP) IN SYSTEMIC LUPUS ERYTHEMATOSUS P. Budde1, S. Vordenbäumen2, H.D. Zucht1, H. Göhler1, P. Schulz-Knappe1, M. Schneider2

(1Dortmund, Germany, 2Düsseldorf, Germany)12:10-12:20 INCREASED SERUM LEVELS OF IFN-LAMBDA 1 CORRELATE WITH TH17 AXIS CYTOKINES AND INDEPENDENTLY TO IFN-ALPHA IDENTIFY PATIENT GROUP WITH HIGHER ORGAN DAMAGE V. Oke1, S. Brauner1, A. Larsson2, J. Gustafsson1, A. Zickert1, I. Gunnarsson1, E. Svenungsson1 (1Stockholm, Sweden, 2Uppsala, Sweden)12:20-12:30 ANGIOGENESIS BIOMARKERS AND DOPPLER ULTRASOUND IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND/OR ANTIPHOSPHOLIPID SYNDROME FOR DIFFERENTIAL DIAGNOSIS BETWEEN PREECLAMPSIA AND DISEASE ACTIVITY E. Rodriguez Almaraz, M. Galindo, E. Gonzalo Gil, A. Usategui, I. Herraiz, P.I. Gomez Arriaga, P. Vallejo, E.A. Lopez Jimenez, A. Galindo (Madrid, Spain)

Scientific Program

37

Casinò Room

11:00-12:30 IMPROVING OUTCOME IN SLE Chairs: R. Cervera (Barcelona, Spain), L. Iaccarino (Padova, Italy)11:00-11:25 Mortality in SLE: how can we improve the survival of our patients? C. Vasconcelos (Porto, Portugal)11:25-11:50 Improving the outcome of pulmonary arterial hypertension in patients with SLE M. Li (Beijing, China)

11:50-12:00 EVALUATION OF SELF REPORTED FATIGUE IN ADULT ITALIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: ASSOCIATION WITH GENERAL HEALTH, QUALITY OF LIFE AND MUSCULOSKELETAL MANIFESTATIONS V. Pacucci, F. Ceccarelli, F.R. Spinelli, C. Perricone, F. Miranda, S. Truglia, C. Alessandri, G. Valesini, F. Conti (Roma, Italy)12:00-12:10 SLE PATIENTS’ CONCERNS AND ADHERENCE TO THERAPY A QUALITATIVE STUDY F. Farinha1, A. Águeda1, F. Freitas2, I. Cunha1, A. Barcelos1

(1Aveiro, Portugal, 2Coimbra, Portugal)12:10-12:20 SOCIAL SUPPORT AND QUALITY OF LIFE IN SLE D. Mazzoni, E. Cicognani (Bologna, Italy)12:20-12:30 DETERMINANTS OF QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS: A SINGLE CENTER EXPERIENCE C. Ancuta, C. Pomirleanu, R. Maxim, C. Belibou, E. Ancuta, C. Iordache, R. Chirieac (Iasi, Romania)

Scientific Program

38

Party Room

11:00-12:30 LUPUS ANIMAL MODELS AND NEW PATHOGENETIC CLUES Chairs: M.E. Gershwin (Davis, USA), M. Khamashta (London, UK)11:00-11:25 Lupus in domestic animals L. Gershwin (Davis, USA)11:25-11:50 Semaphorin3A improves outcome of SLE in NZB mice E. Toubi (Haifa, Israel)11:50-12:10 ROS-dependent fibrinogen function alteration in SLE patients L. Emmi (Firenze, Italy)

12:10-12:20 MICROPARTICLES BIND TO CIRCULATING PHAGOCYTES AND ERYTHROCYTES: A POSSIBLE CLEARANCE MECHANISM RELEVANT TO THE PATHOGENESIS OF SYSTEMIC LUPUS ERYTHEMATOSUS L. Kjær Winberg, C.H. Nielsen, S. Jacobsen (Copenhagen, Denmark) 12:20-12:30 ROLE OF GALECTIN-3 IN PREVENTION AND TREATMENT OF LUPUS GLOMERULONEPHRITIS IN NZB/NZW F1 MICE F. Saccon1, R. Luisetto1, M. Gatto1, M. Beggio1, A. Ghirardello1, M. Fedrigo1, F.L. De Oliveira2, A. Doria1 (1Padova, Italy, 2Rio de Janeiro, Brazil)

Perla Room

12:30-13:00 CLOSING CEREMONY

Scientific Program

39

E-PosterPoster

Poster SessionsPOSTER SESSION 1: FAMILY PLANNING, FERTILITY, PREGNANCY AND NEONATAL CARE

E-POSTER DISCUSSION (Thursday 6 October, 13:30-14:30) Chair: E. Svenungsson (Stockholm, Sweden)P1:2 • ARE LUPUS PATIENTS ON MYCOPHENOLATE COMPLIANT WITH UPDATED PREGNANCY PREVENTION GUIDELINES?B. Canning, V. Gupta, H. Tarakmeh, A. Cove-Smith, R. Rajakariar, A. Pakozdi, D. Pyne(London, UK)P1:3 • EFFECT OF PREGNANCY COUNSELLING PRIOR TO CONCEPTION ON THE OUTCOME OF PREGNANCIES IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PROSPECTIVE STUDYL. Küppers1, O. Sander1, C. Specker2, R. Brinks1, M. Schneider1, R. Fischer-Betz1

(1Düsseldorf, Germany, 2Essen, Germany)P1:4 • RISK FACTORS FOR PREGNANCY MORBIDITY IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES WITHOUT A DEFINED CLINICAL ANTIPHOSPHOLIPID SYNDROMER. Demetrio Pablo, P. Muñoz, L. Riancho-Zarrabeitia, V. Calvo-Río, M. López-Hoyos,V. Martínez-Taboada(Santander, Spain)P1:5 • INFERTILITY AND ASSISTED REPRODUCTIVE TECHNOLOGIES: A MULTICENTER STUDY IN PATIENTS WITH SLE AND APSR. Reggia1, H. Sebbar1, L. Andreoli1, A. Hoxa2, A. Ruffatti2, F. Ceccarelli3, F. Conti3, V. Canti4, P. Rovere Querini4, M. Larosa2, A. Doria2, A. Lojacono1, A. Tincani1

(1Brescia, Italy, 2Padova, Italy, 3Roma, Italy, 4Milano, Italy) P1:6 • RISK FACTORS FOR ADVERSE PREGNANCY OUTCOME IN FIRST-LINE TREATED PREGNANCIES IN APL POSITIVE WOMEN ACCORDING TO DIFFERENT TREATMENT STRATEGIES: RESULTS FROM OUR 30 YEARS’ EXPERIENCE PREGNANCY CLINICM. Lazzaroni, L. Andreoli, F. Lupoli, E. Aggogeri, M. Fredi, E. Bettiga, A. Lojacono, F. Ramazzotto, S. Zatti, A. Tincani(Brescia, Italy)P1:7 • HYDROXYCLOROQUINE IN PRIMARY APS PREGNANT WOMEN WITH TRIPLE POSITIVITY: EFFECTS ON APL LEVELS AND PREGNANCY OUTCOMEC. Garufi, S. Tabacco, S. Salvi, A. Botta, E. Di Pasquo, G. Del Sordo, S. Moresi, M.P. De Carolis, A. Lanzone, S. De Carolis(Roma, Italy)P1:8 • CONTRACEPTIVE COUNSELING AND USE AMONG PORTUGUESE WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: WHAT IS LACKING?F. Aguiar, R. Fonseca, I. Brito (Porto, Portugal)P1:9 • PREVALENCE OF DISEASE IN CHILDREN OF MOTHERS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND OTHER SYSTEMIC AUTOIMMUNE DISEASESE. Ucar Angulo1, A. Pluma2, J.J. Elorz1

(1Bilbao, Spain, 2Barcelona, Spain)

40

E-PosterPoster

Poster SessionsPOSTER DISCUSSION (Thursday 6 October, 10:30-11:00) Chairs: L. Andreoli (Brescia, Italy), M. Tektonidou (Athens, Greece)P1:11 • NEURODEVELOPMENTAL AFFECTION IN CHILDREN BORN TO MOTHERS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROMEM. Hassanien, M. Alzohry, A. Algohee, R. Abdelwakeel, E. Askar, N. Ahmed (Assuit, Egypt)P1:12 • A PREGNANT WOMAN WITH SLE: SEVERE DISEASE FLARE AND SEVERE INFECTIONV. Ramoni1, M. Betelli2, S. Rampello2, S. Maestroni2, M. Meroni2, A.L. Brucato2

(1Pavia, Italy, 2Bergamo, Italy)P1:13 • OUTCOME OF PREGNANCY IN LUPUS NEPHRITIS PATIENTS: DESCRIPTION OF THREE CASESF. Motta, L. Cavagna, R. Caporali, M. Romano, B. Vitolo, F. Beneventi, G. Fasoli, C. Montecucco, V. Ramoni(Pavia, Italy)P1:14 • PREVALENCE OF ABORTIONS AND FETAL ATRIOVENTRICULAR BLOCK IN PATIENTS WITH POSITIVE ANTI-RO AND ANTI-LA ANTIBODIESI. Chalmeta Verdejo, F.M. Ortiz Sanjuán, J. Ivorra Cortés, L. González Puig, E. Grau García,C.M. Feced Olmos, E. Labrador Sánchez, K. Arévalo Sánchez, R. Negueroles Albuixech, J. Fragio Gil, I. Martínez Cordellat, J.L. Valero Sanz, C. Alcañiz Escandell, J.E. Oller Rodríguez, G. Poveda Marín, C. Nájera Herranz, J.A. Román Ivorra(Valencia, Spain)P1:15 • SEVERE FOETAL GROWTH RESTRICTION DUE TO EXTENSIVE PLACENTAL DAMAGE IN A WOMAN WITH ANTINUCLEAR AND ANTI SSA/RO ANTIBODIES. A CASE REPORT.C. Volpe1, E. Tonutti2, L. Zandonà1, A. Custrin1, S. Venturini3, F. Scrimin1

(1Trieste, Italy, 2Udine, Italy, 3Leicester, UK) P1:16 • PREGNANCY OUTCOME IN SYSTEMIC LUPUS ERYTHEMATOSUS IN RELATION TO DISEASE ONSETC. Pamfil, D. Tulbure, L. Damian, T.I. Bolos, I. Felea, I. Filipescu , S. Rednic(Cluj-Napoca, Romania)

41

E-PosterPoster

Poster SessionsPOSTER SESSION 2: INNATE IMMUNITY, AUTOANTIBODIES AND INFECTIONS

E-POSTER DISCUSSION (Thursday 6 October, 13:30-14:30) Chair: A. Ghirardello (Padova, Italy)P2:18 • IFN(ALPHA)-MEDIATED DEREGULATION OF MITOCHONDRIAL DNA CLEARANCE PROMOTES THE AUTOREACTIVE PHENOTYPE OF PERIPHERAL BLOOD MONOCYTES IN HUMAN SYSTEMIC LUPUS ERYTHEMATOSUSK. Gkirtzimanaki1, E. Kabrani1, A. Mplanas1, P. Sidiropoulos1, G. Bertsias1, D. Boumpas1,2, P. Verginis1,2

(1Heraklion, Greece, 2Athens, Greece)P2:19 • IN VITRO IFN ALPHA TREATMENT UP-REGULATE BLYS GENE EXPRESSION IN A HUMAN MONOCYTIC AND MACROPHAGE-DERIVED CELL LINEM. Beggio , A. Ghirardello, R. Luisetto, E. Iori, E. Faggin, L. Punzi, A. Doria(Padova, Italy)P2:20 • LUPUS SYNDROME INDUCED BY ANTI TNF DOES NOT SEEM TO BE RELATED TO THE APPEARANCE OF ANTIBODIES AGAINST THE MEDICATION (ADAB)P. Zufferey, B. Cyrril, M. Perreau, A. Safran, C. Conrad, A. So (Lausanne, Switzerland)P2:21 • SIGLEC-1-POSITIVE PLASMACYTOID DENDRITIC CELLS (PDCS) IN HUMAN PERIPHERAL BLOOD: A SEMI-MATURE AND MYELOID-LIKE SUBSET IMBALANCED IN SLEV. Gerl1, T. Wilhelm2, A. Taddeo1, O. Winter1, R. Biesen1, T. Alexander1, A. Radbruch1, F. Hiepe1

(1Berlin, Germany, 2Heidelberg, Germany)P2:22 • ANTIDFS70 POSITIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND OTHER RHEUMATIC DISEASESM. Guerra, A.P. Cruz, T. Videira, P. Pinto(Vila Nova de Gaia, Portugal)P2:23 • MAPPING TRIM21ALPHA–AUTOANTIBODY INTERACTIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTSE. Grau García, N.M. Do Nascimento, I. Monzó, R. Tejero, S. Morais, J.L. López-Paz, R. Puchades, A. Maquieira, J.A. Román Ivorra, D. Giménez-Romero(Valencia, Spain)P2:24 • ANTI-DSDNA ANTIBODIES ARE NOT CRITICAL TO DIFFERENTIATE CLINICAL PATTERNS IN SLE POPULATION: RESULTS OF TWO STEP CLUSTER ANALYSES OF A MONOCENTRIC SLE COHORTG. De Marchi1, L. Quartuccio1, F. Zuliani1, E. Mansutti2, M. Bond1, S. De Vita1

(1Udine, Italy, 2Gorizia, Italy)P2:25 • STUDYING THE POTENTIAL OF NEUTROPHILS FROM JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (JSLE) PATIENTS FOR PHAGOCYTOSISA. Glaser, H.L. Wright, R.D. Wright, A. Midgley, M. Peak, M.W. Beresford(Liverpool, UK)

42

E-PosterPoster

Poster SessionsP2:26 • IMMUNE RESPONSE (IMMUNOGENICITY AND SAFETY) IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES AFTER PNEUMOCOCCAL CONJUGATE VACCINEZ. Szabó, A. Kulcsár, K. Miklós, N. Hartvig, L. Tóthné Fischer, J. Simon, A. Bányai(Budapest, Hungary)

POSTER DISCUSSION (Thursday 6 October, 10:30-11:00) Chairs: Z. Amoura (Paris, France), F. Franceschini (Brescia, Italy)P2:28 • ACTIVATION OF THE STAT1 PATHWAY BY TYPE 1 AND 2 INTERFERONS AND SUBSEQUENT EFFECT ON NEUTROPHIL APOPTOSISS. Irwin, A. Midgley, R.D. Wright, M. Peak, M.W. Beresford (Liverpool, UK)P2:30 • SERUM 25-OH VITAMIN D IN TREATMENT-NAÏVE SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: RELATION TO DISEASE ACTIVITY, IL-17, AND IL-23D. Shahin1, R. El-Farahaty1, M. Houssen2, S. Machaly1, M. Sallam1, T. Elsaid1, N. Neseem1 (1Mansoura, Egypt, 2Damanhour, Egypt) P2:31 • VITAMIN D DEFICIENCY AND ANTI-C1Q ANTIBODIES AS MARKERS FOR DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUSE.A.H. Omran, N.M. Ismail, E. Mosad, Y.S. Hussien(Assiut, Egypt)P2:32 • ANTI-TOPOISOMERASE 1 ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSOUS: RARE AND FOUND ONLY IN ANTI-DS DNA POSITIVE PATIENTSM. Fredi1, I. Cavazzana1, A. Zanola1, N. Carabellese1, A. Tincani1, M. Mahler2, F. Franceschini1

(1Brescia, Italy, 2San Diego, USA)P2:33 • SEROPOSITIVITY FOR PREVIOUS EPSTEIN BARR VIRUS INFECTION IN THE SWISS SYSTEMIC LUPUS ERYTHEMATOSUS COHORT STUDY (SSCS)L. Schirmbeck1, C. Ribi2, U. Huynh-Do3, D. Dubler1, C. Chizzolini4, M. Trendelenburg1

(1Basel, Switzerland, 2Lausanne, Switzerland, 3Bern, Switzerland, 4Geneva, Switzerland)P2:34 • AUTOANTIBODY RESPONSE TO TROVE2 IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTSE. Grau García, A.M. Juste, N. Do Nascimento, I. Monzó, R. Tejero, S. Morais, J.L. López-Paz, R. Puchades, J.A. Román Ivorra, D. Giménez-Romero (Valencia, Spain)P2:35 • FIRST CASE OF DISSEMINATED MYCOBACTERIUM GORDONAE INFECTION MIMICKING SYSTEMIC LUPUS ERYTHEMATOSUS EXACERBATIONC. Kotsogianni, P. Katsimbri, F. Kontos, N. Danias, D. Boumpas, A. Papadopoulos (Athens, Greece)P2:39 • THE IMPACT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSM. Tikly, M.H. Ngandu Ntumba, A.N. Mvudi (Johannesburg, South Africa)

43

E-PosterPoster

Poster SessionsPOSTER SESSION 3: GENETICS AND PATHOGENESIS OF SLE

E-POSTER DISCUSSION (Thursday 6 October, 13:30-14:30) Chair: C. Sjöwall (Linköping, Sweden)P3:40 • MOLECULAR CHARACTERIZATION OF SLE BY RNA-SEQ: IDENTIFICATION OF GENES AND EXPRESSION-QUANTITATIVE TRAIT LOCI CONTRIBUTING TO PATHOGENESIS, SEVERITY AND TISSUE SUSCEPTIBILITYG. Bertsias1, N. Panousis2, I. Gergiannaki1, M. Tektonidou3, M. Trachana4, A. Banos5, A. Fanouriakis3, C. Pamfil5, E. Dermitzakis2, D. Boumpas3

(1Heraklion, Greece, 2Geneva, Switzerland, 3Athens, Greece, 4Thessaloniki, Greece, 5Cluj-Napoca, Romania)P3:41 • TRANSCRIPTOME PROFILING BY NEXT GENERATION SEQUENCING OF HEMATOPOIETIC PROGENITORS IN MURINE SYSTEMIC LUPUS ERYTHEMATOSUSA. Banos1, M. Grigoriou1, P. Verginis1, C. Nikolaou1, P. Pavlidis2, E. Dermitzakis3, G. Bertsias2, D. Boumpas1

(1Athens, Greece, 2Heraklion, Greece, 3Geneva, Switzerland) P3:42 • DECREASED LUPUS MANIFESTATIONS IN PRISTANE-INDUCED MICRORNA 155-DEFICIENT MICEH. Leiss, W. Salzberger, B. Jacobs, I. Gessl, N. Kozakowski, S. Blüml, A. Puchner, M. Gärtner, B. Niederreiter, T. Shvets, C.W. Steiner, J. Smolen, G.H. Stummvoll (Vienna, Austria)P3:43 • ASSOCIATION OF IRF5 POLYMORPHISMS WITH INCREASED RISK FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN THE POPULATION OF CRETE, A SOUTHERN-EASTERN EUROPEAN GREEK ISLANDM.I. Zervou1, J.M. Dorschner2, Y. Ghodke-Puranik2, D. Boumpas1,3, T.B. Niewold2, G.N. Goulielmos1

(1Heraklion, Greece, 2Rochester, USA, 3Athens, Greece)P3:44 • PHENOTYPICAL CHARACTERISATION OF THE OUTCOME OF HVEM-MEDIATED CO-STIMULATION OF B CELLS. A POTENTIAL MECHANISM INVOLVED IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).A. Seretis1, A. Zampoulaki1, I. Gergianaki1, P. Sidiropoulos1, D. Boumpas1,2, G. Bertsias (1Iraklio, Greece, 2Athens, Greece)P3:45 • MARGINAL-ZONE-LIKE B CELLS IN PERIPHERAL BLOOD AS POSSIBLE BIOMARKERS OF HYPOSPLENISM/ASPLENIA IN SLEZ. Hrncir, D. Vokurkova, M. Drahosova, T. Soukup, J. Toms(Hradec Králové, Czech Republic)P3:47 • MILK FAT GLOBULE EPIDERMAL GROWTH FACTOR 8 GENETIC POLYMORPHISMS IN KOREAN SYSTEMIC LUPUS ERYTHEMATOSUSC. Suh1, J. Woo1, S. Lee2, S. Kim3, S. Hong2

(1Suwon, South Korea, 2Seoul, South Korea, 3Gangeneung, South Korea)

44

E-PosterPoster

Poster SessionsP3:48 • LONG TERM IMMUNOMODULATORY EFFECT IN CIRCULATING B CELL COMPARTMENT OF BELIMUMAB TREATED SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTSJ. Monserrat Sanz1, A. Perez Gómez1, H. Moruno1, A. Gómez LaHoz1, L. Paule1, F. Albarran1, C. Bohorquez1, L. Ruiz1, A.I. Sanchez Atrio1, E. Cuende1, A. Movasat1, M.J. Leon1, D. Diaz1, I. Sanz2, M. Alvarez-Mon1 (1Alcalá de Henares, Spain, 2Atlanta, USA)P3:49 • INHIBITION OF IN VITRO B CELL MATURATION BY NEW CHEMICAL PROBES IN ASSAYS USING BLOOD CELLS FROM PATIENTS WITH SLE AND IIMY. Sundström1, T. Chen1, F. Bergqvist1, M. Sundström1, J. Taunton2, E. Ossipova1,J. Lengqvist1, I. Gunnarsson1, I. Lundberg1, P.J. Jakobsson1, L. Berg1

(1Stockholm, Sweden, 2San Francisco, USA)P3:51 • PLASMA FICOLIN LEVELS AND RISK OF NEPHRITIS IN DANISH PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSN. Tanha, K. Pilely, M. Farschou, P. Garred, S. Jacobsen (Copenhagen, Denmark)

POSTER DISCUSSION (Thursday 6 October, 10:30-11:00) Chairs: A. Alunno (Perugia, Italy), T. Vyse (London, UK)P3:52 • 6 MONTH CHANGE IN REGULATORY T LYMPHOCYTES IS ASSOCIATED WITH DECLINE OF PROTEINURIA WITHIN 5 YEARS IN LUPUS NEPHRITIS PATIENTSB. Foroncewicz, K. Bocian, K. Mucha, A. Wirkowska, A. Truszewska, A. Perkowska-Ptasinska, G. Korczak-Kowalska, L. Paczek(Warsaw, Poland)P3:53 • ANTIOXIDANT RESPONSE IS ALTERED IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH A HIGHER ACCUMULATIVE DAMAGE SCORE AND LONGER EVOLUTIONE. Grau García, M. Fernández Matilla, C.M. Feced Olmos, E. Labrador Sánchez, F.M. Ortiz Sanjuán, N. Fernández-Llanio, K. Arévalo Ruales, R. Negueroles Albuixech, J. Ivorra Cortés, J. Fragio Gil, I. Martínez Cordellat, J.L. Valero Sanz, I. Chalmeta Verdejo, L. González Puig, C. Alcañiz Escandell, J.A. Castellano Cuesta, D. Hervás Marín, L. Olivares González, R. Rodrigo, J.A. Román Ivorra(Valencia, Spain)P3:54 • POLYMORPHISMS IN GENES IN THE IL-17 PATHWAY AND B CELL MEDIATED IMMUNE RESPONSE MODULATE THE DEVELOPMENT OF SPECIFIC AUTOIMMUNE MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUSC. Perricone, C. Ciccacci, F. Ceccarelli, E. Cipriano, C. Alessandri, F.R. Spinelli, S. Rufini, C. Politi, A. Latini, G. Novelli, G. Valesini, P. Borgiani, F. Conti(Roma, Italy)

45

E-PosterPoster

Poster SessionsP3:55 • DNA HYDROXYMETHYLATION IS ASSOCIATED WITH DECREASED ANTIOXIDANT RESPONSE IN SLE PATIENTSE. Grau García, M. Fernández Matilla, C.M. Feced Olmos, E. Labrador Sánchez, F.M. Ortiz Sanjuán, N. Fernández-Llanio, K. Arévalo Ruales, R. Negueroles Albuixech, J. Ivorra Cortés, J. Fragio Gil, I. Martínez Cordellat, J.L. Valero Sanz, I. Chalmeta Verdejo, L. González Puig, C. Alcañiz Escandell, J.A. Castellano Cuesta, D. Hervás Marín, L. Olivares González, R. Rodrigo, J.A. Román Ivorra(Valencia, Spain)P3:57 • ENHANCED IL-7 RECEPTOR SIGNALING IN SLE PROMOTES T-HELPER CELL PROLIFERATION THROUGH UPREGULATION OF MICRORNA-182 AND DOWNREGULATION OF FOXO1T. Alexander, C. Haftmann, R. Riedel, L. Templin, J. Humrich, G.R. Burmester, A. Radbruch, F. Hiepe, F. Mashreghi(Berlin, Germany)P3:62 • PERIPHERAL BLOOD MIR-146A EXPRESSION LEVELS IN SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS PATIENTSR. Shumnalieva, D. Kachakova, S. Monov, R. Kaneva, Z. Kolarov, R. Rashkov(Sofia, Bulgaria)P3:63 • FREQUENCY OF SLE-ASSOCIATED AUTOANTIGEN-SPECIFIC CD4+ T CELLS CORRELATES WITH SLE DISEASE ACTIVITYD. Abdirama1, P. Enghard1, S. Tesch1, J.Y. Humrich2, A. Radbruch1, G.R. Burmester1, G. Riemekasten2

(2Berlin, Germany, 2Lübeck, Germany)P3:64 • TRPC6 AND NEUROPSYCHIATRIC SLE: FROM BEDSIDE TO BENCHG.A. Ramirez, C. Sciorati, E.P. Bozzolo, L. Zagato, L. Citterio, L.A. Coletto, C. Lanzani, P. Rovere-Querini, M.G. Sabbadini, P. Manunta, A.A. Manfredi(Milano, Italy)P3:66 • PHOTOSENSITIVITY TO INDOOR LIGHTING IN DARK SKINNED LUPUS PATIENTSH. Neydani Tarakmeh, J. Peters, R. Rajakariar, A. Cove-Smith, A.S.M. Jawad, D. Pyne(London, UK)

46

E-PosterPoster

Poster SessionsPOSTER SESSION 4: BIOMARKERS AND IMAGING

E-POSTER DISCUSSION (Thursday 6 October, 13:30-14:30) Chair: G. Zandman-Goddard (Holon, Israel)P4:67 • AN ULTRASOUND ASSESSMENT OF THE HAND AND WRIST IN SYSTEMIC LUPUS ERYTHEMATOSUSH.I. Popov, C. Pamfil, M.M. Tamas, I. Szabo, A. Mociran, A. Flestea, S. Rednic (Cluj Napoca, Romania)P4:68 • SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2 (STNFR2) AS A BIOMARKER OF KIDNEY TISSUE DAMAGE AND LONG-TERM RENAL OUTCOME IN LUPUS NEPHRITISI. Parodis1, H. Ding2, A. Zickert1, L. Arnaud1, E. Svenungsson1, C. Mohan2, I. Gunnarsson1

(1Stockholm, Sweden, 2Houston, USA)P4:69 • SERUM ANEXELEKTO (AXL) AS A NOVEL BIOMARKER OF RENAL ACTIVITY, TREATMENT RESPONSE AND LONG-TERM OUTCOME IN PATIENTS WITH LUPUS NEPHRITISI. Parodis1, H. Ding2, A. Zickert1, L. Arnaud1, C. Mohan2, I. Gunnarsson1

(1Stockholm, Sweden, 2Houston, USA)P4:70 • SERUM INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2 (IGFBP2) AS A BIOMARKER OF CLINICAL AND HISTOPATHOLOGICAL TREATMENT RESPONSE IN LUPUS NEPHRITISI. Parodis1, H. Ding2, A. Zickert1, L. Arnaud1, C. Mohan2, I. Gunnarsson1

(1Stockholm, Sweden, 2Houston, USA)P4:71 • THE EXPRESSION OF MICROPARTICLES IN THE BLOOD OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): PHENOTYPIC CHARACTERIZATION AND CLINICAL ASSOCIATIONSF. Mobarrez1, A. Vikerfors1, J. Gustafsson1, I. Gunnarsson1, A. Zickert1, A. Larsson2, D. Pisetsky3, H. Wallén1, E. Svenungsson1

(1Stockholm, Sweden, 2Uppsala, Sweden, 3Durham, USA)P4:72 • DE-CONVOLUTION OF WHOLE BLOOD TRANSCRIPTOMIC DATA FROM A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ABATACEPT IN SYSTEMIC LUPUS ERYTHEMATOSUSS. Bandyopadhyay1, S.E. Connolly1, O. Jabado1, S. Kelly1, M. Maldonado1, R. Westhovens2, P. Nash3, J.T. Merrill4, R. Townsend1

(1Princeton, United States Minor Outlying Islands, 2Leuven, Belgium, 3Brisbane, Australia, 4Oklahoma City, USA)P4:73 • MIR-221-5P, MIR-380-3P, MIR-556-5P, MIR-758-3P AND MIR-3074-3P AS BIOMARKERS OF KIDNEY DAMAGE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSE. Navarro1, L. Pacheco1, H. Lorenzi2, Y. Diaz1, R. Navarro3, L. Almendrales1, E. Rico1, A. Iglesias4, E. Egea1, V. Olave1, G. Aroca1

(1Barranquilla, Colombia, 2La Jolla, USA, 3Santa Marta, Colombia, 4Bogotá, Colombia)

47

E-PosterPoster

Poster SessionsP4:74 • NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AS A BIOMARKER FOR LUPUS NEPHRITISD. Monova, S. Monov, M. Todorova, D. Daskalova (Sofia, Bulgaria)P4:75 • URINARY NEUTROPHIL GELATINASE–ASSOCIATED LIPOCALIN (NGAL) AND MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) AS BIOMARKERS FOR LUPUS NEPHRITIS IN COLOMBIAN SLE PATIENTSJ. Gómez-Puerta, B. Ortiz Reyes, T. Urrego, A.L. Vanegas, C.H. Muñoz, M. Restrepo, L.A. González, G. Vásquez(Medellín, Colombia)P4:76 • ANTI-C1Q LEVELS CORRELATE WITH DISEASE ACTIVITY IN A PROSPECTIVE FOLLOW-UP STUDY OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSL. Branco1, C. Ribi2, U. Huynh-Do3, C. Chizzolini4, M. Trendelenburg1

(1Basel, Switzerland, 2Lausanne, Switzerland, 3Bern, Switzerland, 4Geneva, Switzerland)

P4:78 • ROLE OF THE PODOCYTES IN BIOMARKER PRODUCTION IN JUVENILE LUPUS NEPHRITISR.D. Wright, M.W. Beresford (Liverpool, UK)

POSTER DISCUSSION (Friday 7 October, 10:30-11:00) Chairs: A. Bortoluzzi (Ferrara, Italy), B. Pons-Estel (Rosario, Argentina)P4:79 • DISCORDANCE OF AUTOANTIBODY RESULTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: COMPARISON OF THREE METHODOLOGIESK. Moder, C. Crowson, M. Snyder(Rochester, USA)P4:80 • VITAMIN D, IL-10, IL-17, AND IL-23 AS BIOMARKER FOR DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUST. Senturk, B.G. Cetin, G. Sargin, N. Aydin (Aydin, Turkey)P4:81 • LOW PLASMA LEVELS OF FREE PROTEIN S ARE ASSOCIATED WITH CAROTID INTIMA-MEDIA THICKNESS, COMPLEMENT 3, AND LYMPHOCYTE COUNTS IN SYSTEMIC LUPUS ERYTHEMATOSUSC. Suh1, J. Jung1, S. Lee2, S. Kim3, S. Hong2

(1Suwon, South Korea, 2Seoul, South Korea, 3Gangeneung, South Korea) P4:82 • PROTEOMIC ANALYSIS OF B6.NZMSLE1/SLE2/SLE3 FEMALE MICE KIDNEYS TOWARDS THE DISCOVERY OF LUPUS NEPHRITIS BIOMARKERSO. Nicolaou1, K. Sokratous1, A. Hadjisavvas1, A. Kousios2, B. Lauwerys2, K. Kyriacou1

(1Nicosia, Cyprus, 2Brussels, Belgium)

48

E-PosterPoster

Poster SessionsP4:83 • ALTERATIONS IN THE ENDOCANNABINOID SYSTEM AND SYSTEMIC LUPUS ERYTHEMATOSUSL. Navarini1, P. Mozetic1, D.P.E. Margiotta1, F. Basta1, S. Saracini1, M. Maccarrone2, T. Bisogno1,2, A. Afeltra1

(1Roma, Italy, 2Pozzuoli, Italy)P4:84 • NEXT GENERATION TESTING OF ANTINUCLEAR ANTIBODY (ANA) BY COMBINATION OF SCREENING AND CONFIRMATORY TESTINGD. Roggenbuck1, K. Conrad2, D.P. Bogdanos3, A. Radice4, P.L. Meroni4

(1Senftenberg, Austria, 2Dresden, Germany, 3Larissa, Greece, 4Milano, Italy)P4:85 • ANTI-EPHRIN TYPE-B RECEPTOR 2 (EPHB2) AUTOANTIBODIES: A SPECIFIC AND SENSITIVE TOOL FOR SLE DIAGNOSIS IN LUPUSG.V. Martin1, D.F. Azzouz1, F. Arnoux1, N. Balandraud1, T. Martin2, S. Dubucquoi3, E. Hachulla3, N. Bardin1, L. Chiche1, E. Diot4, J. Roudier1, I. Auger1, N.C. Lambert1

(1Marseille, France, 2Strasbourg, France, 3Lille, France, 4Tours, France)P4:86 • SERUM FERRITIN AS A MARKER OF CLINICAL AND HISTOPATHOLOGICAL RESPONSE TO TREATMENT IN LUPUS NEPHRITISI. Parodis1, H. Ding2, A. Zickert1, L. Arnaud1, C. Mohan2, I. Gunnarsson1

(1Stockholm, Sweden, 2Houston, USA)P4:87 • DICKKOPF-RELATED PROTEIN 1 AND SCLEROSTIN LEVELS IN SYSTEMIC LUPUS ERYTHEMATOSUSS. Koca, A. Karatas, Z. Omercikoglu, F. Erman, K. Sahin (Elazig, Turkey)P4:88 • THE IMMUNOLOGICAL PROFILE OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. A RETROSPECTIVE STUDY CONDUCTED DURING A THREE YEAR PERIOD.N. Zotos, M. Gianniki, I. Tatsina, A. Papadopoulou, E. Mosheta, A. Fasouloglou, C. Georgiou, G. Katagis, D. Bougias, L. Papageorgiou, E. Chrisostomou, C. Briasoulis, C. Mitsis, A. Pournou, N. Tsifetaki(Ioannina, Greece)P4:92 • EVALUATION OF ACCUMULATIVE DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AS A NEW CARDIOVASCULAR RISK FACTORI. Chalmeta Verdejo, E. Labrador Sánchez, F.M. Ortiz Sanjuán, E. Grau García, M. Fernández Matilla, C.M. Feced Olmos, N. Fernández-Llanio, K. Arévalo Ruales, R. Negueroles Albuixech, J. Ivorra Cortés, J. Fragio Gil, I. Martínez Cordellat, J.L. Valero Sanz, L. González Puig, C. Alcañiz Escandell, G. Poveda Marín, C. Nájera Herranz, J.A. Castellano Cuesta, D. Hervás Marín, J.A. Román Ivorra (Valencia, Spain)P4:93 • ROUTINE URINE ANALYSIS FOR PROTEINURIA IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IS NECESSARY. A CASE PRESENTATION.N. Zotos, M. Gianniki, I. Tatsina, A. Papadopoulou, D. Bougias, E. Mosheta, C. Georgiou, G. Katagis, L. Papageorgiou, E. Chrisostomou, A. Fasouloglou, A. Pournou, N. Tsifetaki(Ioannina, Greece)

49

E-PosterPoster

Poster SessionsPOSTER SESSION 5: OLD AND NEW TREATMENTS FOR SLE

E-POSTER DISCUSSION (Friday 7 October, 13:30-14:30) Chair: I. Gunnarsson (Stockholm, Sweden)P5:94 • A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, ASCENDING DOSE STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF CC 220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSR. Furie1, V.P. Werth2, E. Lee3, E. Box4, M. Fondal5, A. Kivitz6, W.W. Chatham7, K.C. Kalunian8, C. Legerton9, J.H. Anolik10, S. Korish11, D.R. Hough11, M. Weiswasser11, S. Choi11, P. Schafer11

(1New Hyde Park, USA, 2Philadelphia, USA, 3Upland, USA, 4Charlotte, USA, 5Stockbridge, USA, 6Duncansville, USA, 7Birmingham, USA, 8San Diego, USA, 9Charleston, USA, 10Rochester, USA,11Summit, USA)P5:95 • THE 3RS STRATEGY: REDUCTION, REPLACEMENT AND REFINEMENT OF DRUG THERAPY IN A MONOCENTRIC SLE PATIENT COHORTA. Taulaigo, I. Figueiredo, F. Cardoso, M. Vicente, M. Fernandes, M. Vasques, M. Ferraz, C. Burgi-Vieira, H. Gruner, A. Lladó, A. Panarra, M.F. Moraes-Fontes (Lisbon, Portugal)P5:96 • RESETTING THE IMMUNE SYSTEM WITH IMMUNOABLATION AND HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ASSOCIATED WITH A NORMALIZATION OF TYPE I INTERFERON (IFN) ACTIVITY IN SLET. Alexander, R. Biesen, C. Kyogoku, J. Grün, G.R. Burmester, R. Arnold, A. Grützkau, F. Hiepe(Berlin, Germany)P5:97 • CORTICOSTEROIDS DOSE AFTER 6 MONTHS OF INDUCTION THERAPY IS ASSOCIATED WITH NON-RENAL ORGAN DAMAGE IN PATIENTS WITH LUPUS NEPHRITISC. Choi, Y. Joo, S. Won, S. Bae(Seoul, South Korea)P5:98 • LONG TERM EFFICACY AND SAFETY OF TACROLIMUS FOR PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSM. Mukai, M. Kondo, H. Kataoka(Sapporo, Japan)P5:99 • FACTORS DETERMINING HYDROXYCHLOROQUINE SERUM LEVELS IN A COHORT OF CHINESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSC. Mok(Hong Kong, Hong Kong)P5:100 • RITUXIMAB INDUCES SHORT-TERM IMPROVEMENT IN SEVERE DISSEMINATED DISCOID LUPUS ERYTHEMATOSUS LESIONS IN THE SETTING OF SYSTEMIC LUPUS ERYTHEMATOSUS ASSOCIATED WITH NEPHRITISA. Saracino, C. Orteu(London, UK)

50

E-PosterPoster

Poster SessionsP5:101 • HYDROXYCHLOROQUINE PROTECTS AGAINST EARLY MYOCARDIAL DYSFUNCTION IN SLEG. Gusetu, C. Pamfil, L. Damian, D. Zdrenghea, S. Rednic(Cluj-Napoca, Romania)P5:102 • MEASUREMENT OF PLASMA MYCOPHENOLIC ACID IN PATIENTS WITH LUPUS NEPHRITIS AND INVESTIGATION OF THE NEED FOR DOSE INDIVIDUALIZATIONE. Neroutsos, S. Marinaki, K. Kolovou, I. Boletis, E. Grika, P. Vlachoyiannopoulos, G. Valsami, A. Dokumetzidis, P. Machairas (Athens, Greece)P5:103 • IMMUNOSUPPRESSION WITH MYCOPHENOLIC ACID: SAFE AND EFFECTIVE INDUCTION AND MAINTENANCE TREATMENT FOR PROLIFERATIVE LUPUS NEPHRITIS PATIENTSS. Marinaki, P. Kriki, K. Kolovou, C. Skalioti, E. Kapsia, P. Sfikakis, I.S. Boletis(Athens, Greece)P5:104 • COMBINATION THERAPY OF MYCOPHENOLATE MOFETIL AND CYCLOSPORINE A FOR INDUCTION TREATMENT OF REFRACTORY LUPUS NEPHRITIS: SUCCESSFUL TREATMENT OF DIFFICULT CASESD. Jesus, M. Rodrigues, J.A.P. Da Silva, L. Inês(Coimbra, Portugal)P5:105 • MEDICAL ADHERENCE OF PATIENTS WITH LUPUS ERYTHEMATOSUS IN GERMANY 2012 – RESULTS OF THE LULA COHORT STUDYG. Chehab1, G.M. Sauer1, J.G. Richter1, R. Brinks1, R. Willers1, R. Fischer-Betz1,B. Winkler-Rohlfing2, M. Schneider1

(1Düsseldorf, Germany, 2Wuppertal, Germany)

POSTER DISCUSSION (Thursday 6 October, 16:15-16:45) Chairs: D. Isenberg (London, UK), F. Puppo (Genova, Italy)P5:106 • CHARACTERIZATION OF THE DIFFERENT HUMAN INTERFERON-ALPHA SUBTYPES INVOLVED IN SYSTEMIC LUPUS ERYTHEMATOSUSA. Mathian, K. Dorgham, F. Cohen-Aubart, M. Hie, J. Haroche, M. Pha, C. Jacob, F. Rozenberg, H. Yssel, G. Gorochov, Z. Amoura (Paris, France)P5:109 • HOW FREQUENT IS REMISSION IN SYSTEMIC LUPUS ERYTHEMATOSUS? REAL LIFE DATA FROM A MONOCENTRIC COHORTR. Vagelli, C. Tani, L. Carli, C. Stagnaro, S. Vagnani, M. Mosca(Pisa, Italy)P5:110 • SUCCESSFUL TREATMENT WITH BELIMUMAB AFTER INADEQUATE RESPONSE TO PREVIOUS THERAPEUTIC REGIMENS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. REAL LIFE EXPERIENCE.P. Athanassiou1, A. Tzanavari1, C. Katsavouni1, T. Banti1, I. Kostoglou-Athanassiou2

(1Thessaloniki, Greece, 2Athens, Greece)

51

E-PosterPoster

Poster SessionsP5:111 • SYSTEMIC LUPUS ERYTHEMATOSUS RELATED-THROMBOCYTOPENIA SUCCESSFULLY TREATED WITH BELIMUMAB AFTER RITUXIMAB FAILUREG. De Marchi, L. Quartuccio, L. Corazza, F. Zuliani, S. De Vita(Udine, Italy)P5:112 • CONCEPT OF SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (S1P1R) MODULATION IN AUTOIMMUNE DISEASESC. Seemayer, S. Bosset, A. Vaclavkova, B. Hennessy, V. Breu, D. D’Ambrosio(Allschwil, Switzerland)P5:113 • THE RITUXILUP PROTOCOL: A CASE REPORT OF INNOVATION AND THERAPEUTIC SUCCESSC. Vidal1,2, V. Bernardino1, F. Lourenço1, F. Carvalho1, N. Riso1, A. Panarra1, M.F. Moraes-Fontes1

(1Lisbon, Portugal, 2Ponta Delgada, Portugal) P5:114 • TARGETING THE TYPE I INTERFERON SYSTEM IN SLEL. Rönnblom(Uppsala, Sweden)P5:115 • MAJOR IMPROVEMENT IN REFRACTORY SLE WITH BELIMUMABS. Pinheiro, B. Duarte, A.S. Borges, M.J.P. Lopes, M. Silva(Lisbon, Portugal)

52

E-PosterPoster

Poster SessionsPOSTER SESSION 6: ORGAN INVOLVEMENT, FLARE, REMISSION AND DAMAGE

E-POSTER DISCUSSION (Friday 7 October, 13:30-14:30) Chair: G.H. Stummvoll (Vienna, Austria)P6:116 • PREDICTION OF CHRONIC DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS USING NEURAL NETWORKSF. Ceccarelli1, M. Sciandrone2, C. Perricone1, G. Galvan2, F. Morelli2, L.N. Lucente3, I. Leccese1, L. Massaro1, E. Cipriano1, F.R. Spinelli1, C. Alessandri1, G. Valesini1, F. Conti1

(1Roma, Italy, 2 Firenze, Italy, 3Coimbra, Portugal)P6:117 • CLINICAL FEATURES AND PROGNOSES OF ACUTE TRANSVERSE MYELITIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSS. Ahn1, S. Hong2, D. Lim2, B. Ghang2, Y. Kim2, C. Lee2, B. Yoo2

(1Guri, South Korea, 2Seoul, South Korea)P6:118 • RESORBTION OF IMMUNE DEPOSITS IN MEMBRANOUS LUPUS NEPHRITIS FOLLOWING TREATMENT - A TOOL TO EVALUATE RESPONSE?A. Zickert, K. Lannfelt, B. Sundelin Von Feilitzen, I. Gunnarsson(Stockholm, Sweden)P6:119 • EFFECTS OF RISK FACTORS FOR METABOLIC SYNDROME AND THE COMPONENTS OF METABOLIC SYNDROME ON THE QUALITY OF LIFE OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A STRUCTURAL EQUATION MODELING APPROACHS. Lee, J. Lee, J. Kang, Y. Yim, J. Kim, K. Lee, L. Wen, D. Park(Gwangju, South Korea)P6:120 • SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RESPONDER INDEX [SRI(4)] RESPONSE IS ASSOCIATED WITH GLOBAL BENEFIT IN PATIENTS WITH MODERATE TO SEVERE SLER. Furie1, L. Wang2, J. Drappa2, G. Illei2

(1Great Neck, USA, 2Gaithersburg, USA)P6:121 • CLINICAL PARAMETERS RELATED WITH ORGAN DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM KOREAN LUPUS NETWORK (KORNET) REGISTRYJ. Kim, J.N. Kim, C.W. Lee, J.Y. Choe, S.K. Kim(Daegu, South Korea)P6:122 • WHAT IF “NEUROLUPUS” ISN’T SYSTEMIC LUPUS ERYTHEMATOSUS AFTER ALL? ANTIPHOSPHOLIPID ANTIBODIES INCREASE NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTI-SMITH ANTIBODIES MIGHT PROTECT FROM ITR. Faria, M. Fidalgo, G. Carvalheiras, D. Mendonca, C. Vasconcelos (Porto, Portugal)

53

E-PosterPoster

Poster SessionsP6:123 • APPLYING LUPUS LOW DISEASE ACTIVITY STATE DEFINITION TO A COHORT OF PORTUGUESE LUPUS PATIENTSA. Daniel, G. Eugénio, J.A. Pereira da Silva, L. Inês(Coimbra, Portugal)P6:124 • JUVENILE-ONSET LUPUS NEPHRITIS: INVESTIGATING THE ROLE OF THE GLOMERULAR ENDOTHELIAL CELLS IN NOVEL URINE BIOMARKER PRODUCTIONP. Dimou1, A. Midgley1, M. Peak1, S.C. Satchell2, R.D. Wright2, M.W. Beresford1

(1Liverpool, UK, 2Bristol, UK)P6:125 • MRI-BASED CONNECTOMICS AS A TOOL TO EXPLORE NEUROLOGICAL INVOLVEMENT IN SLEG.A. Ramirez, M.A. Rocca, L. Moiola, E.P. Bozzolo, P. Preziosa, L. Vacchi, F. Sangalli, P. Rovere-Querini, M.G. Sabbadini, M. Filippi, A.A. Manfredi (Milano, Italy)P6:126 • ASSESSMENT OF MICROVASCULAR DAMAGE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS - CAPILLAROSCOPIC EXAMINATIONM. Parvu, S. Coman, S. Voidazan, M. Tilinca(Targu Mures, Romania)P6:127 • BONE MINERAL DENSITY AND FRACTURE RISK IN A COHORT OF SYSTEMIC LUPUS ERYTHEMATOSUS WOMENC. Ancuta, C. Pomirleanu, R. Maxim, C. Belibou, E. Ancuta, R. Chirieac(Iasi, Romania)

POSTER DISCUSSION (Thursday 6 October, 16:15-16:45) Chairs: M. Aringer (Dresden, Germany), M. Zen (Padova, Italy)P6:128 • SYSTEMIC LUPUS ERYTHEMATOSUS ACTIVITY IS ASSOCIATED WITH OXIDATIVE STRESS WITHOUT ANY IMPAIRMENT IN THE PLASMA ANTIOXIDANT CAPACITYK. Kerboua, A. Boumediene(Oran, Algeria)P6:131 • TO INVESTIGATE CAUSES FOR ADMISSIONS AND OUTCOMES IN HOSPITALISED SLE PATIENTS ADMITTED TO A TERTIARY HOSPITAL IN SOUTH AFRICAS. Karolia, M. Tikly (Johannesburg, South Africa)P6:132 • MULTIPLE AUTOIMMUNE SYNDROME MIGHT PROTECT FROM SJÖGREN’S SYNDROME-SPECIFIC ORGAN INVOLVEMENT – A CLINICAL, IMMUNOLOGICAL AND GENETIC ANALYSISM. Fidalgo, R. Faria, C. Carvalho, A. Gomes, G. Carvalheiras, D. Mendonca, F. Farinha, B. Martins da Silva, C. Vasconcelos (Porto, Portugal)

54

E-PosterPoster

Poster SessionsP6:133 • FULL HOUSE IMMUNOFLUORESCENCE PATTERN NEPHROPATHY: IS IT ALWAYS LUPUS NEPHRITIS?C. Catalano, M. Garjau, M. Depierreux, K. Van Den Houte, J.P . Riga, T. Mihailescu, T. Balfroid, K.M. Wissing(Brussels, Belgium)P6:135 • WHEN THE EYES DON’T SEE: A RARE PRESENTATION OF SYSTEMIC LUPUS ERYTHEMATOSUST. Ramires1, A.C. Araújo2, I. Lúcio2, A.L. Basílio2, L. Costa2, L. Vieira2, R. Flores2, A. Panarra2, M.F. Moraes-Fontes2

(1Évora, Portugal, 2Lisbon, Portugal)P6:136 • PLATELET TO LYMPHOCYTE RATIO AND NEUTROPHIL TO LYMPHOCYTE RATIO IN LUPUS NEPHRITIS PATIENTSD. Monova, S. Monov, M. Todorova, E. Peneva(Sofia, Bulgaria)P6:137 • THE PREDICTIVE VALUE OF PHYSIOLOGICAL SCORES AND SPECIFIC INDICES FOR PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS ADMITTED TO AN INTENSIVE CARE UNITA. Kalla, J.A. Venter, M. Bloch, R. Raine(Cape Town, South Africa)P6:139 • TRANSVERSE MYELITIS: A NEUROPSYCHIATRIC MANIFESTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS VERSUS NEUROMYELITIS OPTICAC. Pamfil, I. Szabo, N. Draghici, D. Muresanu, A. Petcu, S. Rednic (Cluj-Napoca, Romania)P6:140 • URINE LEUKOCYTES AS NON-INVASIVE MARKERS OF LUPUS NEPHRITISC. Marañón, J.C. Herrero, C. Fernández, I. Jiménez, M.E. Alarcón-Riquelme (Granada, Spain)P6:141 • POLYARTERITIS NODOSA VASCULAR LESIONS AS EARLY MANIFESTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS - A CASE REPORT AND SYSTEMATIC LITERATURE REVIEWR. Padoan, M. Felicetti, L. Nalotto, A. Ortolan, F. Schiavon, A. Doria(Padova, Italy)P6:143 • LUPUS NEPHRITIS IN QATARN. Abdulla, O. Fituri, F. Alam, I. Mujeeb, E. Elsayed, M. Hammoudeh, N. Hadwan(Doha, Qatar)P6:144 • BELIMUMAB INDUCES REMISSION OF DERMATOLOGIC MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUSP. Athanassiou1, C. Katsavouni1, A. Tzanavari1, T. Banti1, C. Kalinou1, I. Kostoglou-Athanassiou2 (1Thessaloniki, Greece, 2Athens, Greece)

55

E-PosterPoster

Poster SessionsP6:145 • ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA) IN LUPUS NEPHRITISM.C. Ditto1, R.A. Sinico1, B. Trezzi1, P. Sarzi-Puttini1, G. Moroni1, F. Raffiotta1, P. Messa1, S. Quaglini2, A. Radice1

(1Milano, Italy, 2Pavia, Italy)P6:146 • ACUTE CARDIAC FAILURE AND IGA NEPHROPATHY: AN UNCOMMON SLE ONSETO. Magnani, M. Pellecchio, E. Penza, G. Murdaca, S. Negrini, F. Puppo(Genova, Italy)P6:147 • CARDIAC INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTSM. Nechita Ferreira, M. Lutea, T. Verbeet, J. Castro Rodriguez, M. Morissens, R. Karmali, J.J. Body (Bruxelles, Belgium)P6:148 • SHRINKING LUNG SYNDROME AS A PULMONARY COMPLICATION OF JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORTJ. Ilisson, C. Pruunsild (Tartu, Estonia)P6:150 • EVALUATION OF CURRENT AND AT THE ONSET CLINICAL MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTSI. Chalmeta Verdejo, M. Fernández Matilla, C.M. Feced Olmos, E. Grau García, E. Labrador Sánchez, F.M. Ortiz Sanjuán, N. Fernández-Llanio, K. Arévalo Ruales, J. Ivorra Cortés, J. Fragio Gil, I. Martínez Cordellat, J.L. Valero Sanz, L. González Puig, C. Alcañiz Escandell, R. Negueroles Albuixech, G. Poveda Marín, C. Nájera Herranz, J.A. Castellano Cuesta, D. Hervás Marín, J.A. Román Ivorra(Valencia, Spain)P6:151 • SYSTEMIC LUPUS ERYTHEMATOSUS AND AUTO IMMUNE HEPATITIS: A CASE REPORTM. Albuquerque, M.J. Sousa, R. Ribeiro, M. Menezes, J.G. Sousa, G. Sousa(Lisbon, Portugal)P6:152 • SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)-ADOLESCENT PSYCHOSIS. A CASE DESCRIPTION.N. Zotos, M. Gianniki, I. Tatsina, V. Grammeniaths, A. Papadopoulou, E. Mosheta, C. Georgiou, G. Katagis, D. Bougias, E. Chrisostomou, A. Fasouloglou, A. Pournou, N. Tsifetaki (Ioannina, Greece)

56

E-PosterPoster

Poster SessionsPOSTER SESSION 7: CARDIOVASCULAR DISEASE AND ANTIPHOSPHOLIPID ANTIBODIES

E-POSTER DISCUSSION (Friday 7 October, 13:30-14:30) Chair: K. de Leeuw (Groningen, The Netherlands)P7:153 • EVALUATION OF THROMBOTIC RISK IN PATIENTS WITH POSITIVE ANTIPHOSPHOLIPID ANTIBODIES WITHOUT CLINICAL CRITERIA FOR THE DISEASER. Demetrio-Pablo, P. Muñoz, V. Calvo-Río, L. Riancho-Zarrabeitia, M. López-Hoyos, V. Martínez-Taboada (Santander, Spain)P7:154 • RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS EXHIBIT SIMILAR DEGREE OF SEVERITY OF SUBCLINICAL ATHEROSCLEROSIS. RESULTS FROM A CROSS-SECTIONAL STUDY IN A POPULATION OF NORTHWESTERN SPAIN.L. Riancho-Zarrabeitia, A. Corrales, N. Vegas-Revenga, L. Domínguez-Casas, V. Portilla, R. Blanco, M.A. González-Gay(Santander, Spain)P7:156 • CORONARY ARTERY CALCIFICATION IN DANISH SLE PATIENTS WITHOUT KNOWN CARDIOVASCULAR DISEASE: COMPARISON WITH MYOSITIS, DIABETES AND THE GENERAL POPULATIONS. Kay1, A.C.P. Diederichsen1, L.P. Diederichsen1, M.K. Poulsen1, J. Lambrechtsen2,F.H. Steffesen3, N.P. Sand4, H. Mickley1, J. Lindholt1, S. Jacobsen5, J. Hjelmborg1, A. Voss1

(1Odense, Denmark, 2Svendborg, Denmark, 3Vejle, Denmark, 4Esbjerg, Denmark, 5Copenhagen, Denmark)P7:157 • PREVALENCE OF COMORBIDITIES IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS: A COMPARATIVE, REGISTER-BASED STUDY WITH EMPHASIS IN CARDIOVASCULAR DISEASEI. Rúa-Figueroa1, M. Fernández Castro2, J.M. Pego-Reigosa3, C. Sanchez-Piedra2, F.J. López-Longo2, V. Martínez-Taboada4, J. Calvo-Alén5, A. Olivé6, M. Galindo2, R. Blanco4, F. Alonso2, C. Erausquin1, J.L. Andreu2

(1Las Palmas, Gran Canaria, 2Madrid, Spain, 3Vigo, Spain, 4Santander, Spain, 5Cantabria, Spain, 6Barcelona, Spain)P7:158 • DISEASE CHARACTERISTICS, SURVIVAL ANALYSIS AND MORTALITY IN A SINGLE CENTRE COHORT OF PATIENTS WITH ANTIPHOSPHOLIPID SYNDROMEB. Artim Esen, O. Pehlivan, Y. Sahinkaya, T. Yuce, S. Kamali, A. Gul, L. Ocal, M. Inanc(Istanbul, Turkey)P7:159 • THE RISK OF CARDIOVASCULAR MORTALITY AND DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS – A DANISH NATIONWIDE POPULATION-BASED COHORT STUDYM. Hermansen, J. Lindhardsen, C. Torp-Pedersen, M. Faurschou, S. Jacobsen(Copenhagen, Denmark)

57

E-PosterPoster

Poster SessionsP7:160 • ARTERIAL WALL STIFFNESS IN SYSTEMIC LUPUS ERYTHEMATOSUSK. Jensen-Urstad, M. Herlitz Lindberg, J. Gustafsson, I. Gunnarsson, E. Svenungsson(Stockholm, Sweden)P7:161 • SERUM GALECTIN-3 BINDING PROTEIN IS A NOVEL INDEPENDENT PREDICTOR OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSN. Rasmussen1, C. Sjöwall2, A.S. Peretz1, N.H. Heegaard1, S. Jacobsen1, C.T. Nielsen1

(1Copenhagen, Denmark, 2Linköping, Sweden)P7:162 • INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM (IPMN): A NEW MANIFESTATION OF CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME (CAPS)?L. Savey1, J.C. Piette1, J. Bellanger1, Z. Amoura1, L. Palazzo1, A. Sauvanet2, J.F. Pouget-Abadie3, P. Sogni1, J. Emmerich1, N. Costedoat-Chalumeau1

(1Paris, France, 2Clichy, France, 3Niort, France)P7:163 • PULSE WAVE VELOCITY AS A CARDIOVASCULAR DISEASE RISK FACTOR IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTSS. Xavier Pires1, S.I. Xavier Pires1,2, M. Cunha1, S. Freitas1, P. Cunha1, G. Alves1, J. Cotter1

(1Guimarães, France, 2Porto, Portugal)P7:164 • IS THERE PERIPHERAL VASCULOPATHY IN SYSTEMIC LUPUS ERYTHEMATOSUS? A VIDEOCAPILLAROSCOPY STUDYC. Pomirleanu, R. Maxim, C. Ancuta (Iasi, Romania)

POSTER DISCUSSION (Friday 7 October, 10:30-11:00) Chairs: N. Agmon-Levin (Tel-Hashomer, Israel), R. Foti (Catania, Italy)P7:165 • SUBCLINICAL ATHEROSCLEROSIS IN SLE PATIENTS WITH LOW DISEASE ACTIVITY IS ASSOCIATED WITH BODY MASS INDEX, HDL CHOLESTEROL, AND USAGE OF NSAID AND GLUCOCORTICOIDSC. Suh1, J. Jung1, S. Lee2, S. Kim3, S. Hong1

(1Suwon, South Korea, 2Seoul, South Korea, 3Gangeneung, South Korea)P7:166 • ENDOTHELIAL DYSFUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITHOUT PREVIOUS CARDIOVASCULAR EVENTSM. Taraborelli, E. Sciatti, I. Bonadei, V. Terlizzi, M. Fredi, R. Zani, G. Cancarini, A. Tincani, F. Franceschini, E. Vizzardi, I. Cavazzana(Brescia, Italy)P7:167 • PRECLINICAL VASCULAR DAMAGE IN PREMENOPAUSAL SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AND IN CONTROLS; ARE THERE ANY DIFFERENCES?A. Paini, L. Andreoli, M. Salvetti, F. Dall’Ara, S. Piantoni, C. Donini, C. Agabiti Rosei, F. Bertacchini, D. Stassaldi, A. Tincani, M.L. Muiesan (Brescia, Italy)P7:168 • IS HYPERURICEMIA AN INDEPENDENT RISK FACTOR FOR ARTERIAL THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS?C. Mok(Hong Kong, Hong Kong)

58

E-PosterPoster

Poster SessionsP7:169 • 41 CASES OF ANTIPHOSPHOLIPID ANTIBODY SYNDROMEM. Silva, R. Ribeiro, P. Barreto, S. Pinheiro(Lisbon, Portugal)P7:170 • ECHOCARDIOGRAM FINDINGS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSI. Al-Homood, A. Mohammed, M. Aljahlan(Riyadh, Saudi Arabia)P7:172 • A STUDY OF THE CARDIOVASCULAR DISEASE RISK FACTORS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSN. Zotos, M. Gianniki, I. Tatsina, A. Papadopoulou, E. Mosheta, A. Fasouloglou, C. Georgiou, G. Katagis, D. Bougias, C. Mitsis, C. Briasoulis, E. Chrisostomou, A. Pournou, N. Tsifetaki(Ioannina, Greece)P7:173 • UNDIAGNOSED ANTIPHOSPHOLIPID SYNDROME IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL IMPLICATIONS –A CASE REPORT-E. Zanatta, S. Cuffaro, M. Tonello, F. Cozzi, A. Doria, A. Ruffatti(Padova, Italy)

59

E-PosterPoster

Poster SessionsPOSTER SESSION 8: CHALLENGES IN MANAGEMENT OF SLE (1)

E-POSTER DISCUSSION (Friday 7 October, 13:30-14:30) Chair: L.I. Czirjak (Budapest, Hungary)P8:174 • THE CRETAN LUPUS REGISTRY “LETO”: INCIDENCE AND PREVALENCE OVER A 15-YEAR PERIOD, CLINICAL FEATURES AND ENVIRONMENTAL FACTORS IN A HOMOGENEOUS, SOUTHERN-EUROPEAN POPULATIONI. Gergiannaki1, A. Repa1, M. Tzanakakis1, A. Fanouriakis1,3, C. Adamichou1, A. Pompieri1, G. Spyrou1, E. Kabouraki1, M. Mamoulaki1, I. Tzanakis1, L. Chatzi3, P. Sidiropoulos1,2, D. Boumpas1,2, G. Bertsias1

(1Heraklion, Greece, 2Athens, Greece, 3Chania, Greece)P8:175 • DIAGNOSTIC CHALLENGE OF DIFFERENT NEUROPSYCHIATRIC LUPUS MANIFESTATIONS: PERFORMANCE OF AN ATTRIBUTION ALGORITHM IN THIS WIDE SPECTRUM DISORDERA. Bortoluzzi1, A. Fanouriakis2, S. Appenzeller3, G. Bertsias2, L. Carli4, F. Conti5, L.T. Costallat3, G. De Marchi6, S. De Vita6, A. Doria7, G. Ferraccioli5, E. Gremese5, A. Mathieu8, M. Mosca4, E. Murphy9, C. Nalli10, M. Piga8, C.A. Scirè11, J.G. Hanly9, M. Govoni1, A. Tincani10, P. Tomietto12 , G. Valesini4, M. Zen7

(1Ferrara, Italy, 2Heraklion, Greece, 3Campinas, Brazil, 4Pisa, Italy, 5Roma, Italy, 6Udine, Italy, 7Padova, Italy, 8Cagliari, Italy, 9Nova Scotia, Canada,10Brescia, Italy, 11Milano, Italy, 12Trieste, Italy)P8:176 • INFLAMMATORY BACK PAIN IS INCREASED IN SLE; A LONGITUDINAL COHORT STUDYS. Yavuz1, Y. Yilmaz1, A. Yazici2, B. Ozulu1, I. Karolak1

(1Istanbul, Turkey, 2Kocaeli, Turkey)P8:178 • HOW GOOD A CARE ARE WE REALLY PROVIDING TO OUR LUPUS PATIENTS?S. Arora, A. Nika, W. Sequeira, J. Block, M. Jolly(Chicago, USA)P8:179 • CLINICAL AND SEROLOGICAL DIFFERENCES OF DISEASE EXPRESSION IN LATE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS FROM A PORTUGUESE COHORTF. Aguiar, R. Fonseca, I. Brito (Porto, Portugal)P8:180 • SERUM URIC ACID AS A PROGNOSTIC FACTOR OF PULMONARY HYPERTENSION: SYSTEMATIC REVIEW AND META-ANALYSISJ. Jun1, K. Park2, H. Kim1, H. Ahn1, S. Yim2

(1Seoul, South Korea, 2Suwon, South Korea) P8:181 • ANALYSIS OF SLE PATIENTS HOSPITALIZATION IN A 10-YEARS PERIODL. Massaro, F. Ceccarelli, F.R. Spinelli, C. Alessandri, F. Conti, G. Valesini(Roma, Italy)P8:182 • DISABILITY IN SLE PATIENTS WITH JOINT INVOLVEMENT: ASSOCIATION WITH ACTIVITY INDICESE. Cipriano, F. Ceccarelli, C. Perricone, L. Massaro, G. Capalbo, F. Natalucci, F.R. Spinelli, C. Alessandri, F. Conti, G. Valesini(Roma, Italy)

60

E-PosterPoster

Poster SessionsP8:183 • SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE STUDY OF MUCOCUTANEOUS FEATURES IN SOUTH AFRICANSK. Koch, L. Pillay, M. Tikly(Johannesburg, South Africa)P8:185 • LUPOSOMES - CIRCULATING EXTRACELLULAR VESICLES IN SYSTEMIC LUPUS ERYTHEMATOSUSN. Heegaard, O. Østergaard, C.T. Nielsen, J.T. Tanassi, L.V. Iversen, S. Jacobsen (Copenhagen, Denmark)

POSTER DISCUSSION (Friday 7 October, 10:30-11:00) Chairs: F. Ceccarelli (Roma, Italy), R. Furie (Great Neck, USA)P8:186 • JACCOUD ARTHROPATY: CLINCAL AND SEROLOGICAL CHARCTERISTICSC. Bazzani, I. Cavazzana, M. Fredi, M. Taraborelli, A. Tincani, F. Franceschini(Brescia, Italy)P8:187 • DIAGNOSIS, EVALUATION AND MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IN CHINESE ADULTS: RECOMMENDATIONS FROM CHINESE SLE TREATMENT AND RESEARCH GROUP (CSTAR)J. Qian, M. Li, Y. Wang, X. Zeng(Beijing, China)P8:188 • DO PATIENTS WITH SYSTEMIC LUPUS GET BETTER QUALITY OF CARE IN LUPUS CLINICS THAN IN GENERAL RHEUMATOLOGY CLINICS?S. Arora, A. Nika, J. Block, W. Sequeira, M. Jolly(Chicago, USA)P8:189 • TEN-YEAR SURVIVAL AND ITS PREDICTORS IN A RETROSPECTIVE INCEPTION COHORT OF SLE PATIENTS FROM A CROATIAN TERTIARY CENTERI. Padjen, M. Erceg, M. Cerovec, M. Mayer, R. Stevanovic, B. Anic (Zagreb, Croatia)P8:190 • ASSESSMENT OF WORKABILITY OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. PRELIMINARY RESULTS FROM THE “RETURN TO WORK CLINIC” AT S. CAMILLO HOSPITAL IN ROME.A. Iuliano, G.D. Sebastiani, I. Prevete, G. Minisola(Roma, Italy)P8:192 • FACTORS WHICH DEFINE THE EARLIEST DISEASE SEVERITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND THE PATIENTS’ RESPONSE TO THE PHARMACEUTICAL TREATMENTN. Zotos, M. Gianniki, I. Tatsina, A. Papadopoulou, E. Mosheta, A. Fasouloglou, C. Georgiou, G. Katagis, D. Bougias, L. Papageorgiou, C. Briasoulis, C. Mitsis, E. Chrisostomou, A. Pournou, N. Tsifetaki(Ioannina, Greece)

61

E-PosterPoster

Poster SessionsP8:195 • VITAMIN D STATUS IN PHOTOTYPE VI SENEGALESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A CASE CONTROL STUDYF. Ly, H. Mansouri, S. Ndongo, H. Hakim, M.T. Ndiaye Diop, A. Diop, A. Diouf, F. Fall, A. Leye, N.D. Sall(Dakar, Senegal)P8:196 • JUVENILE VERSUS ADULT-ONSET SYSTEMIC LUPUS ERYTHEMATOSUSNEPHRITIS: DISTINCT CLINICAL, LABORATORY AND HISTOPATHOLOGICALFEATURESR. Smerla, C. Mavragani, G. Fragoulis, H.M. Moutsopoulos(Athens, Greece)P8:197 • DIAGNOSTIC CRITERIA AND PATIENTS’ OUTCOME: STUDY OF 82 ADULT PATIENTS IN AN INTERNAL MEDICINE UNITC. Chalhoub Gihane(Ars Laquenexy, France)P8:198• FACTORS INFLUENCING ON HEALTH-RELATED QUALITY OF LIFE IN KOREAN FEMALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSS.J. Moon, Y.S. Hong, J.K. Min(Seoul, South Korea)P8:199 • CHILDHOOD LUPUS IN A REFERRAL MEDICAL CENTER: PREDOMINANCE OF CUTANEOUS MANIFESTATIONSD. Albert(Lebanon, USA)P8:200 • CAN WE IDENTIFY WHO BENEFITS FROM MYCOPHENOLATE MOFETIL IN SYSTEMIC LUPUS ERYTHEMATOSUS? A SYSTEMATIC REVIEWC. Mendoza Pinto1, C. Pirone2, B. Parker3, I. Bruce3

(1Puebla, Mexico, 2Roma, Italy, 3Manchester, UK)P8:201 • ILLNESS NARRATIVES AMONG SLE PATIENTS. AN ANTHROPOLOGICAL PERSPECTIVE OF LIVING WITH CHRONIC DISEASE.E. Forgione(Roma, Italy)

62

E-PosterPoster

Poster SessionsPOSTER SESSION 9: CHALLENGES IN MANAGEMENT OF SLE (2)

POSTER DISCUSSION (Friday 7 October, 16:15-16:45) Chairs: M. Gatto (Padova, Italy), M. Urowitz (Toronto, Canada)P9:202 • CAPABILITIES OF EUROPEAN LUPUS GROUPS; MEMBERS OF LUPUS EUROPEB. Rubio, K. Lerstrom(Romford, UK)P9:203 • OUTCOME OF FILIPINO CHILDREN WITH LUPUS NEPHRITIS TREATED WITH A MODIFIED TREATMENT REGIMEN USING CYCLOPHOSPHAMIDEM. Collante, C. Bernal(Manila, Philippines)P9:204 • HEALTH-RELATED QUALITY OF LIFE (HRQOL), THE EMOTIONALITY AND THE DAY-TO-DAY PROBLEM SOLVING AND COPING IN LUPUS PATIENTA. Dominguez, M.I. Casado Morales(Madrid, Spain)P9:205 • A RARE LUNG MANIFESTATION IN SYSTEMIC LUPUS ERYTHEMATOSUS: THE SHRINKING LUNG SYNDROME. A CASE REPORT AND REVIEW OF THE MOST RECENT LITERATURE.M. Felicetti1, A. Berti2, A. Volpe3, F. Boccafoglio3, G. Interlandi3, G. Paolazzi3

(1Padova, Italy, 2Milano, Italy, 3Trento, Italy)P9:206 • MULTIPLE AUTOIMMUNE SYNDROME: EXPERIENCE OF AN INTERNAL MEDICINE UNITC. Chalhoub Gihane, S. Ricois, P. Okamba, G. Brabant(Ars Laquenexy, France)P9:208 • DEPRESSION IN SAUDI PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A MULTICENTER STUDYI. Al-Homood1, N. Omran2, A. Alwahibi1, M. Aldosoghi1, A. Alharthy1, G. Aljohani1

(1Riyadh, Saudi Arabia, 2Makkah, Saudi Arabia)P9:209 • SIX CASES OF MACROPHAGE ACTIVATION SYNDROME AS PRESENTING MANIFESTATION OF SYSTEMIC LUPUS ERYTHEMATOSUSF. Dall’Ara, I. Cavazzana, M. Frassi, M. Taraborelli, M. Fredi, F. Franceschini, L. Andreoli, A. Tincani, P. Airò (Brescia, Italy)P9:210 • CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN NAIROBI, KENYAE. Genga1, G. Oyoo1, F. Otieno1, B. Shiruli1, J. Odhiambo1, E. Omondi2

(1Nairobi, Kenya, 2Meru, Kenya)

63

E-PosterPoster

Poster SessionsP9:211 • A STUDY AND RECORD OF THE EARLY SYMPTOMS OF SYSTEMIC LUPUS ERYTHEMATOSUS IN A HOSPITAL IN NORTHWESTERN GREECEN. Zotos, M. Gianniki, I. Tatsina, A. Papadopoulou, E. Mosheta, A. Fasouloglou, C. Georgiou, G. Katagis, D. Bougias, L. Papageorgiou, E. Chrisostomou, A. Pournou, N. Tsifetaki(Ioannina, Greece)P9:212 • CHRONIC DAILY HEADACHE DETERIORATE TO THE QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSC. Son, J.M. Kim, S.H. Kim(Daegu, South Korea)P9:213 • MULTIDISCIPLINARY PATIENT-ORIENTED CARE IN SYSTEMIC LUPUS ERYTHEMATOSUS: KNITTING THE REFERENCE NETWORKL. Damian1, S. Rednic1, I. Catana1, I. Kacso1, A. Maniu1, M. Man1, L. Bene1, R. Ciortea1, C. Baican1, A. Hutanu1, D. Dan2, C. Pamfil1

(1Cluj-Napoca, Romania, 2Bucharest, Romania)P9:214 • HEMOPHAGOCYTIC SYNDROME IN SLE: A TERTIARY REFERRAL CENTER EXPERIENCEL. Damian, C. Pamfil, M. Sfichi, P. Vele, I. Felea, S.P. Simon, I. Hotea, N. Hagau, S. Rednic (Cluj-Napoca, Romania)P9:216 • HYPOALBUMINEMIA AND TRANSVERSE SINUS THROMBOSIS IN A PATIENT WITH SLE: A CASE REPORTS. Reyes, J. Lichauco(Quezon City, Philippines)P9:217 • CALCIUM INTAKE OF ADULT POPULATION IN BOGOTA AND ASSOCIATION WITH HYPOVITAMINOSIS D. NEXT STEP: THE SAME ANALYSIS IN 100 PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOUS.R. Guzman Moreno, L.G. Piñeros, A. Teheran, L.M. Pombo, J. Flechas, M.C. Mejia, K. Guzman,J. Garcia, J. Bustillo(Bogota, Colombia)P9:219 • SYSTEMIC LUPUS ERYTHEMATOSUS COMPLICATED BY THROMBOTIC THROMBOCYTOPENIC PURPURAM. Gerosa, R. Gualtierotti, M. Pisati, P.L. Meroni(Milano, Italy)P9:221 • LIMBIC ENCEPHALITIS IN A SLE PATIENT WITH PAPILLARY THYROID CARCINOMAS. Pinheiro, B. Duarte, M. Amaral, J. Oliveira, R. Estriga, M. Silva, S. Oliveira(Lisbon, Portugal)P9:222 • SLE IN MALES- SHORT CASE SERIES- MEN MAY HAVE MORE NEUROLOGICAL DISEASE!S. Nallasivan, Y. Ravindran (Madurai, India)

64

E-PosterPoster

Poster SessionsP9:223 • FAMILIAL COLD AUTOINFLAMMATORY SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS: A PUZZLING ASSOCIATIONL. Damian1, C. Marinescu1, C. Pamfil1, M. Velcherean-Nicola2, I. Filipescu1, I. Felea1, L. Muntean1, S. Rednic1

(1Cluj-Napoca, Romania, 2Deva, Romania)P9:225 • NEONATAL LUPUS ERYTHEMATOSUS PRESENTING WITH HEART BLOCK AND PNEUMONITIS: A DIFFICULT CASEF. Aguiar, S. Pereira, M. Rodrigues, G. Rocha, H. Guimarães, I. Brito (Porto, Portugal)P9:228 • ROLE OF NEUROIMAGING IN REFRACTORY NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS (NPSLE)E. Silvagni, A. Bortoluzzi, F. Bergossi, M. Borrelli, M. Padovan, M. Govoni(Ferrara, Italy)P9:230 • A RAPID SEQUENCE OF EVENTSM. Silva, J. Oliveira, P. Barreto, S. Pinheiro(Lisbon, Portugal)P9:231 • SKIN CANCER IN A COHORT OF SYSTEMIC LUPUS ERITHEMATOSUSC. Genitori, M. Taraborelli, M.T. Rossi, M. Fredi, I. Cavazzana, A. Tincani, P.G. Calzavara Pinton, F. Franceschini(Brescia, Italy)P9:234 • COLLAGEN INDUCED ARTHRITIS (CIA): A MURINE MODEL TO EVALUATE THE ROLE OF SERPINB3 IN PREVENTION AND TREATMENT OF ARTHRITIS IN AUTOIMMUNE DISEASESS. Bindoli1, R. Luisetto1, N. Bassi1, M. Beggio1, A. Ghirardello1, L. Iaccarino1, P. Pontisso1,Y. Shoenfeld2,3, A. Doria1

(1Padova, Italy, 2Tel-Hashomer, Israel, 3Tel Aviv, Israel)

65

ABSTRACT BOOKAll submitted abstracts, accepted as oral presentation or poster, have been published in Clinical Experimental Rheumatology Supplement. The abstract book is available in an electronic format on a USB stick and will be given at the registration desk with the congress kit.

BREAKFAST MEETINGSDuring these sessions the experts will discuss a clinical case. The breakfast meetings will take place on Thursday 6 and Friday 7 October between 8.00-9.00 and during the session a breakfast will be served.

GUIDELINES FOR CHAIRPERSONS AND SPEAKERSGuidelines for chairpersons• Locate your session room in due time and find yourself there at least 10 minutes before the beginning of the session• Respect the timing allowed to the session and to each presentation• All presentations, discussions and questions must be in EnglishGuidelines for speakers• Follow the instructions indicated in the paragraph “Audiovisual Instructions”• Locate your session room in due time and find yourself there at least 10 minutes before the beginning of the session to meet the chairpersons• Respect the timing allowed for your presentation• All presentations, discussions and questions must be in EnglishAudiovisual instructionsSpeakers presenting in oral sessions are requested to submit their presentations to the slide centre at least 1 hour before the start of their session. Personal computers cannot be connected to the projectors in the session room and presentations cannot be loaded directly on the computer of the session rooms. If speakers created their presentation using a system different from Windows (such as OS MAC or Linux), they are kindly requested to provide presentations in a Windows-compatible format and to come earlier to the slide centre, in order to have enough time to solve possible compatibility issue.At the slide centre our hostess will be happy to welcome and help speakers. Experienced technicians will assist speakers in transferring the slides and make changes if needed. Slide presentations will then be uploaded to the respective session room.

ORAL COMMUNICATIONSOral presentations are limited to 7 minutes followed by 3 minutes of discussion.Participants presenting in oral sessions are requested to submit their presentations to the slide centre at least 1 hour before the start of their session.

Scientific Information

66

POSTERDuring the meeting are planned two different poster discussions. One will be held at the E-Poster Stations, and the other one will be done in front of the Poster board. All abstracts accepted as posters, independently of type of discussion, will be displayed in the Poster Area (Level 2) from Wednesday October 5 to Saturday October 8. Posters must be hanged on the first day and removed at the end of the Congress. If authors will not remove their posters by 14.30, they will be thrown away. The organizing secretariat cannot be addresses for any responsibility in poster loss or destruction.Guidelines for poster display:• Poster board will be 100 x 250 cm (width x height)• Each poster has been given a number and should be fixed on the board marked with the same number. Please refer to the Posters’ Secretariat Desk to check your number.• Only pins can be used to hang the posters. Materials will be available onsite.

The E-Poster Discussion during the lunch and the Poster Disussion during the coffee break will be guided and moderated by a chairperson. All presentations, discussions and questions must be in English.

E-POSTERSThe best posters have been selected for an E-Poster presentation. The discussion will take place at the E-Poster Stations (LCD Screens), placed in the Lunch and Poster Area on Level 2, during the lunch on Thursday 6 and Friday 7 October from 13.30 to 14.30. The electronic poster has been structured with 3 slides (1st slide: Objective, Design and Method - 2nd slide: Results - 3rd slide: Conclusions) and each author has 3 minutes for the presentation and 2 minutes for the discussion.

E-POSTERS DISCUSSION SESSIONS

STATION 1 STATION 2 STATION 3 STATION 4

Poster session 1: Family planning,

fertility, pregnancy and neonatal care

Posters fromn. 1 to 10

Poster session 2: Innate immunity,

autoantibodies and infections Posters from

n. 17 to 27

Poster session 3: Genetics and

pathogenesis of SLE Posters from

n. 40 to 51

Poster session 4: Biomarkers and imaging

Posters fromn. 67 to 78

Poster session 5: Old and new treatments

for SLE Posters fromn. 94 to 105

Poster session 6: Organ involvement, flare,

remission and damage Posters fromn. 116 to 127

Poster session 7: Cardiovascular disease and antiphospholipid

antibodies Posters fromn. 153 to 164

Poster session 8: Challenges in

management of SLE (1) Posters fromn. 174 to 185


THURSDAY 6 OCTOBER 2016 - 13.30-14.30 HRS

FRIDAY 7 OCTOBER 2016 - 13.30-14.30 HRS

67

POSTER DISCUSSION SESSIONSThe presenting authors of the posters not selected for the E-Poster Presentation, are kindly requested to be available close to their posters in the following days and times:Thursday 6 October from 10.30 to 11.00 during the coffee breakPoster Session n. 1 (Posters from n. 11 to 16)Poster Session n. 2 (Posters from n. 28 to 39)Poster Session n. 3 (Posters from n. 52 to 66)Thursday 6 October from 16.15 to 16.45 during the coffee breakPoster Session n. 5 (Posters from n. 106 to 115)Poster Session n. 6 (Posters from n. 128 to 152)Friday 7 October from 10.30 to 11.00 during the coffee breakPoster Session n. 4 (Poster from n. 79 to 93)Poster Session n. 7 (Poster from n. 165 to 173)Poster Session n. 8 (Poster from n. 186 to 201)Friday 7 October from 16.15 to 16.45 during the coffee breakPoster Session n. 9 (Poster from n. 202 to 234)

BEST PAPERSThe best 10 abstracts will be selected by the Scientific Committee and the presenters (under 40) will receive a prize during the Closing Ceremony. Winners who will not be present will not receive the prize.

GRANT SIRThe Italian Society of Rheumatology (SIR) provided 15 grants to participants selected for oral or poster presentations which have reached a high score and considered to be particularly meritorious by the Referees. Only the presenter of a selected abstract

was eligible for the grant and he/she should be a SIR member, younger than 40 years old and in good standing with the membership fees. The winners are invited to be present during the Closing Ceremony on October 8 at 12.30 in order to collect the certification of the SIR Award.

CME ACCREDITATIONThe 10th European Lupus Meeting is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 10th European Lupus Meeting is designated for a maximum of (or 'for up to') 15 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.


68

Social Media

The 10th European Lupus Meeting will be a unique conference that provides a world class platform for clinicians and scientists to present, discuss, and exchange expertise in the most rapidly evolving area of related to the treatment of lupus pathology. Join other international scientists and clinicians and be a part of this unique opportunity to share cutting edge findings and network with distinguished experts in the field.

#10LupusMeeting


70

ORGANIZING SECRETARIAT

AIM Group International - Milan OfficeVia G. Ripamonti, 129 - 20141 Milan, ItalyPh. +39 02 566011 - Fax. +39 02 [email protected] www.lupus2016.org

CONGRESS VENUEPalazzo del CasinòLungomare Marconi 30 - Venice, Italy

HOW TO REACH THE VENUE

From the Airport Marco Polo Alilaguna boat - red line, direct to the Lido Santa Maria Elisabetta http://www.alilaguna.it/en (50 min.)Express bus to Piazzale Roma and then take ACTV line (see below)From Piazzale Roma (car park)ACTV line 1 to the Lido (58 min.)ACTV lines 5.1, 6 to Lido (35 min.)ACTV line 5.2 to Lido (48 min.)From Tronchetto (car park)ACTV line 2 to San Zaccaria (28 min.) then either Line 1 or Line 5.1 to Lido (17 min.)or Ferry (35 min.)From the Railway StationACTV Line 1 (55 min.)ACTV line 5.1 (40 min.) or line 5.2 (45 min.)

All the water bus above stop in Lido Santa Maria Elisabetta and not in front of the congress venue. (See page n.75 for the bus lines in Lido)

General Information

10 EUROPEAN LUPUS M E E T I N G

th

71

General InformationFLOORPLANFIRST LEVEL

3

SECOND LEVEL

1

4 5 6 REG

ISTR

ATIO

N

CLOACKROOM

PERLA ROOM

PARTY ROOM

FACULTY ROOM

SLIDE CENTRE

ACCESS TO 2ND LEVEL

WELCOME COCKTAILLUNCH &

POSTER AREA

ACCESS TO 1ST LEVEL

TOILETTE

TOILETTE

ENTRANCE

EXHIBITORSBristol-Myers Squibb - Space n.1

F. Hoffmann La Roche Ltd -Space n. 6

GlaxoSmithKline - Space n. 3

Inova Diagnostics - Space n. 4

Janssen Cilag - Space n. 5

Medipan - Space n. 2

2

MEETINGROOMS

CASINO' ROOM

TOILETTE

TOILETTE

TOILETTE

72

OPENING HOURSRegistration Desk Exhibition

Wednesday, October 5 11.00 – 20.00 11.00 – 20.00Thursday, October 6 08.00 – 19.00 08.00 – 18.30

Friday, October 7 08.00 – 19.00 08.00 – 18.30Saturday, October 8 08.00 – 13.00 09.00 – 13.00

LANGUAGEThe official language is English. No simultaneous translation will be provided.

ACCESS TO THE CONGRESSParticipants are kindly requested to always wear their name badge during all congress activities. The badge will admit to the scientific sessions, exhibition area, coffee breaks and lunches.

What colour is your badge?Participants TRANSPARENT Faculty REDExhibitors and Press GREEN

CERTIFICATES OF ATTENDANCECertificates will be delivered to all regularly registered participants during the meeting.

OPENING CEREMONY AND WELCOME COCKTAILThe Opening Ceremony of the Congress will be held on October 5 at 18.30 in the Perla Room. At the end of the Opening Ceremony a Welcome Cocktail will be held at the second level near the poster area.

COFFEE BREAKS AND LUNCHESCoffee breaks will be offered in the exhibition area and lunches in the poster area at the second level.

CLOACKROOMCloakroom and luggage storage facilities are available in the congress venue.

WI-FIFree Wi-Fi is available in the first level of the congress venue and in Casinò Room at the second level.Each participant will receive a different password at the registration desk. Please keep the password for the whole duration of the meeting.

TRANSPORTION CARDAll participants who have registered with one of the packages (A, B, Deluxe) will receive a City Card Transportation. The card is valid for unlimited rides with the public transportation system (ACTV lines) from 5 to 9 October. Please note that the card cannot be used to get to the airport.

General Information

73

OFFICIAL CARRIERThe airlines members of SKYTEAM are the official carriers of LUPUS 2016. For further information visit the website www.lupus2016.org

INSURANCECongress organizers cannot accept liability for personal injuries or for loss of or damage to property belonging to congress participants, either during or as a result of the Congress.

NO-SMOKINGSmoking in the meeting area is not allowed.

MOBILE PHONESDelegates are kindly requested to set their mobile phones on silent mode in the halls where scientific sessions are being held.

BATTERY MULTI-CHARGERAt the GSK booth you can find a battery multi-charger where you can charge your mobile phone, smartphone, tablet, etc. It’s highly safe because each user can lock the device in a small cabinet with a plug and keep the key.

PRIVACY DISCLOSURE AND PUBLISHING OF IMAGESPursuant to article 13 of Legislative Decree no. 196/2003, the personal data of the participants, their videos and photos made during the event, will be used by AIM Italy s.r.l. for purposes related to the communication and the valorization of the event.Such personal data will be communicated only to those people who are in charge of the activities necessary to the aforementioned purposes. Photos and videos will be also published on the website and social networks of AIM Group International (and on the website and social networks of the event, if any). The treatment will be carried out with appropriate tools ensuring security and confidentiality and may be also carried out by computerized tools that are able to memorize, manage and transmit the personal data.The data controller is AIM Italy s.r.l., with legal seat in Milan, Via Giuseppe Ripamonti 129, vat no. 00943621003, e-mail address [email protected] regard to the personal data granted, included photos and videos, each participant can exercise the rights set forth in article 7 of Legislative Decree n. 196/2003 by contacting the data controller.

General Information

74

REGISTRATIONSREGISTRATION FEE (All fees are 22% VAT included)Delegate € 650,00Student/Trainee* € 370,00Healthcare Professional € 370,00Developing Countries** € 400,00Patient*** € 30,00

* In order to benefit from the special fee, the delegate is asked to submit the status confirmation (approval letter signed by the Head of Department) at the Registration Desk.** Developing countries registration fee refers to Low income and Lower-middle-income economies, as defined according to the World Bank Country Classification. *** The registration is free only for members of the executive committee of the Lupus Europe Association, members of Gruppo LES Italiano or presenting author of an oral communication or poster.

The fee includes: • Admission to the scientific sessions• Welcome Cocktail on 5 October• Congress bag with complete meeting materials• Certificate of attendance• Access to the exhibition and poster area• Coffee breaks and lunches, as indicated in the program

PAYMENTSPayments onsite are possible in cash (in Euro) or by credit card (American Express, VISA, Eurocard/Master Card). Please note that due to the Italian Law, it is forbidden to transfer cash between different subjects for an amount exceeding € 3.000,00.

NAME CHANGESName changes onsite are subject to an handling fee of € 50,00 (VAT 22% included). A new registration form for each replacement will be required.

LUPUS DINNERFriday, October 7 - hrs 20.30 at Pisani Moretta Palace(for the faculty and registered participants who bought the ticket - € 100,00 VAT included )Please note that the number of participants for this event is limited. Registrations to the Lupus Dinner will be treated on a first-come-first served basis.

General Information

75

General Information

16211319

121

20

10

184222

15

6924

17

5118323

Stop line A

Stop line V16

211319

121

20

10

184222

15

6924

17

5118323

Stop line A

Stop line V

16211319

121

20

10

184222

15

6924

17

5118323

Stop line A

Stop line V

HOTEL MAP & TRANSPORTATION

1 - Belvedere2 - Best Western Biasutti3 - Ca' del Moro4 - Grand Hotel Ausonia & Hungaria5 - Grand Hotel Excelsior6 - La Meridiana7 - Palazzo Giovanelli8 - Petit Palais9 - Quattro Fontane10 - Rigel11 - Rivamare12 - Riviera

BUS LINES LIDOHOTELSA Faro Rocchetta - Malamocco Lido S.M.E. - P.le RavàB Lido S.M.E. - MalamoccoC Via Parri - Ca’ Bianca - S.Gallo Lido S.M.E.V Lido S.M.E. - Gran Viale S.M.E. lungomare Marconi - via Colombo11 Pellestrina – Lido S.M.E.

13 - Russo Palace14 - Sant'Elena15 - Venezia 200016 - Viktoria Palace17 - Villa Albertina18 - Villa Angelica19 - Villa Edera20 - Villa Laguna/Laguna Suites21 - Villa Mabapa22 - Villa Pannonia23 - Villa Paradiso24 - Villa Stella

VENICE

7

14

LIDO

LIDOSANTA MARIA

ELISABETTA

78

Sponsored Session

THURSDAY 6 OCTOBER, 2016

Perla Room

12.30-13.30 CURRENT ISSUES IN THE MANAGEMENT OF SLE IN A CLINICAL PRACTICE SETTING Chair: A. Doria (Padova, Italy) Speakers: M. Scheinberg (San Paolo, Brazil), A. Tincani (Brescia, Italy)

SATELLITE SYMPOSIUM

79

Authors IndexAAbdelwakeel R. 40Abdirama D. 15, 45Abdul Gafor A.H. 16Abdulla N. 54Abidi F. 14Abrignani S. 21Adamichou C. 13, 59Afeltra A. 26, 30, 48Agabiti Rosei C. 57Aggogeri E. 39Agmon-Levin N. 28, 34, 57Águeda A. 37Aguiar E. 39Aguiar F. 59, 64Ahmed M. 34Ahmed N. 40Ahn H. 59Ahn S. 52Airò P. 23, 62Alam F. 54Alarcón-Riquelme M.E. 17, 21, 23, 54Albarran F. 44Albert D. 61Albuquerque M. 55Alcañiz Escandell C. 40, 44, 45, 48, 55Aldosoghi M. 62Alegre J. 24Alessandri C. 11, 12, 14, 17, 18, 20, 26, 31, 37, 44, 52, 59Alexander T. 23, 41, 45, 49Algazzar I. 34Algohee A. 40Alharthy A. 62Al-Homood I. 58, 62Aljahlan M. 58Aljohani G. 62Almendrales L. 46Aloe G. 35Alonso F. 56Al-Shaghana M. 10Alunno A. 12, 44Alvarez-Mon M. 44Alves G. 57Alwahibi A. 62Alzohry M. 40Amaral M. 63Amengual O. 34Amin S. 17Amital H. 10Amoura Z. 16, 32, 42, 50, 57Ancuta C. 37, 53, 57Ancuta E. 37, 53Andreoli L. 14, 23, 26, 30, 33, 39, 40, 57, 62Andreu J.L. 56Ángeles U. 30Anic B. 60Anolik J.H. 49Apostolidou E. 20Appenzeller S. 59

Aprahamian T. 34Araújo A.C. 54Arévalo Ruales K. 44, 45, 48, 55Arévalo Sánchez K. 40Aringer M. 13, 32, 53Armenia S. 22Arnaud L. 19, 25, 28, 46, 48Arnold R. 49Arnoux F. 48Aroca G. 46Arora S. 59, 60Artim Esen B. 26, 56Askar E. 40Athanassiou P. 50, 54Atsumi T. 34Auger I. 48Aydin N. 47Azzouz D.F. 48

BBae S. 49Baican C. 63Balandraud N. 48Balboa V. 27Baldini M. 20Baldissera E. 20, 30Balestrieri E. 33Balfroid T. 54Banas D. 14Bandyopadhyay S. 46Banos A. 43Banti T. 50, 54Bányai A. 42Banzato A. 33Barbati C. 11, 14, 20Barcelos A. 37Bardin N. 48Barini A. 10Barreto P. 58, 64Barshack I. 10Bartoloni Bocci E. 14, 30Bashi T. 10Basílio A.L. 54Bass D. 15Bassi N. 64Basta F. 48Basta G. 12Battezzati P.M. 27Batty D.S. 36Bazzani C. 60Beggio M. 12, 14, 38, 41, 64Belibou C. 37, 53Bellanger J. 57Ben Ami D. 10Bene L. 63Beneventi F. 40Benzaquén N. 29Berden J.H.M. 11, 20Beresford M.W. 41, 42, 47, 53Berg L. 44Bergossi F. 64

Bergqvis F. 44Beriain J.H. 27Bernal C. 62Bernardino V. 51Bertacchini F. 57Bertero M.T. 28Berti A. 62Bertolo M. 15Bertsias G. 13, 20, 32, 41, 43, 59Betelli M. 40Bettiga E. 39Bettio S. 14, 16, 18, 29Biesen R. 41, 49Bijl M. 24Bindoli S. 64Bisen R. 23Bisogno T. 48Bistoni O. 12Blanco R. 56Blank M. 10Bloch M. 54Block J. 59, 60Blüml S. 43Boccafoglio F. 62Bocian K. 44Body J.J. 55Bogdanos D.P. 48Bohgaki T. 34Bohorquez C. 44Boletis I. 9, 20, 50Bolos T.I. 40Bombaci M. 21Bombardieri S. 9Bonadei I. 57Bond M. 41Bonegio R. 34Bootsma H. 35Borges A.S. 51Borghi M.O. 33Borgiani P. 17, 44Borrelli M. 64Bortoluzzi A. 14, 47, 59, 64Bosset S. 51Boteanu A.L. 25Botta A. 39Bougias D. 48, 55, 58, 60, 63Boumediene A. 53Boumpas D. 13, 17, 20, 24, 41, 42, 43, 59Box E. 49Bozzolo E.P. 20, 45, 53Brabant G. 62Branco L. 26, 47Brauner S. 36Breu V. 51Briasoulis C. 48, 58, 60Brinks R. 39, 50Brito I. 39, 59, 64Brohawn P. 9Brucato A.L. 29, 30, 40Bruce I. 16, 22, 61Brunner H. 25

80

Bruno R.M. 22Budde P. 13, 36Bultink I.E.M. 24Burgi-Vieira C. 49Burmester G.R. 12, 15, 23, 45, 49Bustillo J. 63Buyon J.P. 29, 30, 34

CCacoub P. 30Calafiore R. 12Calvo-Alén J. 13, 24, 27, 35, 56Calvo-Río V. 39, 56Calzavara Pinton P.G. 64Campbell I. 25Cancarini G. 57Canestri S. 10Canning B. 39Canofari C. 35Cantatore F. 30Canti V. 28, 39Canzona A. 24Capalbo G. 31, 59Caporali R. 30, 40Capozzi A. 11Carabellese N. 42Cardoso F. 49Carli L. 18, 22, 50, 59Carman J. 14Carmona-Sáez P. 23Carvalheiras G. 13, 52, 53Carvalho C. 13, 53Carvalho F. 51Casado Morales M.I. 62Casano F. 14Casian A. 25Castagno I. 28Castellano Cuesta J.A. 44, 45, 48, 55Castiglioni M.T. 28Castro Rodriguez J. 55Catalano C. 54Catana I. 63Cattani P. 10, 11Cauli A. 31Cavagna L. 40Cavazzana I. 42, 57, 60, 62, 64Ceccarelli F. 11, 12, 14, 17, 18, 20, 26, 31, 37, 39, 44, 52, 59, 60Ceribelli A. 27Cerovec M. 60Cervera R. 33, 34, 37Cesareo M. 35Cetin B.G. 47Chalhoub Gihane C. 61, 62Chalmeta Verdejo I. 40, 44, 45, 48, 55Chan T.M. 16Chatham W.W. 49Chatzi L. 59Chehab G. 50Cheng Q. 9, 23Chen T. 44

Chiche L. 48Chighizola C. 30Chirieac R. 37, 53Chizzolini C. 20, 26, 27, 42, 47Choe J.Y. 52Choi C. 49Choi S. 49Chowdhary V. 17Chrisostomou E. 48, 55, 58, 60, 63Chrysanthopoulou A. 20Ciccacci C. 17, 44Ciccia F. 11Cicognani E. 37Ciortea R. 63Cipriano E. 17, 18, 26, 31, 44, 52, 59Citterio L. 45Clancy R. 29Clarke A. 23Cohen-Aubart F. 50Cohen I.R. 36Colasanti T. 11, 14, 31Coletto L.A. 28, 45Collante M. 62Coman S. 53Congia M. 31Conigliaro P. 30, 35Connolly S.E. 46Conrad C. 41Conrad K. 48Conti F. 11, 12, 14, 17, 18, 20, 26, 31, 37, 39, 44, 52, 59Corazza L. 51Corrado A. 30Corrales A. 56Cortini A. 17Costa L. 54Costallat L.T. 59Costanzi S. 19Costedoat-Chalumeau N. 29, 30, 34, 57Cotter J. 57Cove-Smith A. 39, 45Cozzi F. 58Crosti M.C. 21Crowson C. 47Cruz A.P. 41Cruz-Reyes C. 30Cuadrado M. 16Cuende E. 44Cuffaro S. 58Cunha I. 37Cunha M. 57Cunha P. 57Cunninghame Graham D. 17Cunningham M. 14Custrin A. 40Cutolo M. 10, 29, 30Cyrril B. 41Czirjak L.I. 59

DD’Ambrosio D. 51D’Angelo S. 30D’Cruz D. 13, 16, 25Dahan S. 10Dall’Ara F. 23, 30, 34, 57, 62Damian L. 40, 50, 63, 64Dan D. 63Danias N. 42Daniel A. 32, 53Daroca G. 35Da Silva J.A.P. 22, 26, 50Daskalova D. 47Dayer J.M. 36De Carolis M.P. 39De Carolis S. 39Del Barrio R. 35de Leeuw K. 24, 35Deligny C. 34Del Rosso S. 28Del Sordo G. 39De Marchi G. 14, 41, 51, 59Demetrio Pablo R. 39, 56De Oliveira F.L. 38Depierreux M. 54Dermitzakis E. 43De Santis M. 27de Toro F.J. 24De Vita S. 14, 41, 51, 59Dhawan T. 34Díaz Barreiro A. 21Diaz D. 44Diaz Y. 46Diederichsen A.C.P. 56Diederichsen L.P. 56Diez E. 27Di Mario C. 10, 11Dimou P. 53Ding F. 24Ding H. 46, 48Diop A. 61Diot E. 48Diouf A. 61Di Pasquo E. 39Di Pilla M. 22Ditto M.C. 55Dokumetzidis A. 50Dolhain R.J.E.M. 24Dominguez A. 62Domínguez-Casas L. 56Do Nascimento N. 42Do Nascimento N.M. 41Donini C. 57Dorgham K. 50Doria A. 8, 9, 12, 14, 15, 16, 18, 26, 29, 30, 38, 39, 41, 54, 58, 59, 64, 78Dörner T. 12, 21Dorschner J. 17Dorschner J.M. 43Draghessi G. 35Draghici N. 54Drahosova M. 43

81

Drappa J. 9, 52Duarte B. 51, 63Dubler D. 26, 42Dubucquoi S. 48

EEastman W. 15Edar M.F.J. 27Edwards L. 15Egea E. 46Eisenberger U. 26El-Farahaty R. 42Elorz J.J. 39Elsaid T. 42Elsayed E. 54Elserougy E. 34Elvin K. 19Emmerich J. 57Emmi G. 14Emmi L. 14, 38Enghard P. 12, 15, 45Erausquin C. 24, 56Erceg M. 60Erman F. 48Ernste F. 17Estriga R. 63Eugénio G. 32, 53

FFacciotti F. 21Faggin E. 41Falanga M. 24Fall F. 61Fanouriakis A. 13, 43, 59Fan W. 17Farewell V. 13Faria R. 13, 52, 53Farinha F. 37, 53Farschou M. 44Fasoli G. 40Fasouloglou A. 48, 55, 58, 60, 63Faurschou M. 56Favaro M. 30Feced Olmos C.M. 40, 44, 45, 48, 55Fedrigo M. 12, 38Felea I. 40, 63, 64Felicetti M. 54, 62Fernandes M. 49Fernández C. 54Fernández Castro M. 56Fernández-Llanio N. 44, 45, 48, 55Fernández M. 27Fernández Matilla M. 44, 45, 48, 55Ferraccioli G. 10, 11, 19, 28, 59Ferraz M. 49Fidalgo M. 13, 52, 53Figueiredo I. 49Figus F. 31Fikry I. 34Filipescu I. 40, 64Filippi M. 53

Fischer-Betz R. 30, 39, 50Fituri O. 54Flavell R.A. 21Flechas J. 63Flestea A. 46Flores R. 54Fondal M. 49Fonseca R. 39, 59Forgione E. 61Forni F. 11Foroncewicz B. 44Foti R. 30, 57Fox N.L. 15Fragio Gil J. 40, 44, 45, 48, 55Fragoulis G. 61Franceschini F. 42, 57, 60, 62, 64Frangou E. 20Frassi M. 62Fredi M. 39, 42, 57, 60, 62, 64Freitas F. 37Freitas S. 57Fridkin M. 10Friebus-Kardash J. 26Fritsch-Stork R. 24Frostegård J. 21Furie R. 9, 14, 15, 26, 49, 52, 60

GGabba A. 31Gabrielli A. 10, 30Gagliani N. 21Gakiopoulou C. 20Galeazzi M. 17Galicier L. 34Galindo A. 36Galindo M. 24, 27, 36, 56Galvan G. 52Gámir Gámir M.L. 25Garcia J. 63Garjau M. 54Garred P. 44Garrote Corral S. 25Gärtner M. 43Garufi C. 11, 31, 39Gatto M. 12, 14, 16, 18, 29, 38, 62Gayet V. 30Geginat J. 21Generali E. 27, 30Genga E. 62Genitori C. 64Georg I. 21Georgiou C. 48, 55, 58, 60, 63Gergianaki I. 13, 43Gergiannaki I. 43, 59Gerhardsson J. 19Gerli R. 12, 14, 30, 35Gerl V. 41Gerosa M. 14, 30, 63Gershwin L. 38Gershwin M.E. 10, 21, 38Gessl I. 21, 43

Ghang B. 52Gherardini R. 22Ghiadoni L. 22Ghirardello A. 12, 14, 16, 38, 41, 64Ghodke-Puranik Y. 43Giacomelli R. 14Gianniki M. 48, 55, 58, 60, 63Gigante M.R. 10, 11, 19, 28Gilkaite I. 36Giménez-Romero D. 41, 42Givol O. 10Gkirtzimanaki K. 41Glaser A. 41Göhler H. 13, 36Goldenberg D.M. 15Gomes A. 53Gomez Arriaga P.I. 36Gómez LaHoz A. 44Gómez-Puerta J. 47Gonsiorek W. 14González-Gay M.A. 56González L.A. 47González M. 35González Puig L. 40, 44, 45, 48, 55Gonzalo Gil E. 36Gordijn S. 35Gordon C. 13Gordon D. 15Gorochov G. 50Goulielmos G.N. 43Govoni M. 14, 25, 30, 59, 64Grados D. 24Grammeniaths V. 55Grau García E. 40, 41, 42, 44, 45, 48, 55Greenstein L. 22Gremese E. 10, 11, 19, 28, 59Grigoriou M. 43Grika E. 33, 50Groark J. 15Groot N. 24Gruner H. 49Grün J. 49Grützkau A. 49Gualtierotti R. 63Guerra M. 41Guettrot-Imbert G. 30Guimarães H. 64Gu J. 24Gul A. 26, 56Gunnarsson I. 19, 36, 44, 46, 48, 49, 52, 57Gupta V. 39Gusetu G. 50Gustafsson J. 19, 36, 46, 57Guzman K. 63Guzman Moreno R. 63

HHabib D. 34Habte S. 14

82

Hachulla E. 34, 48Hadjisavvas A. 47Hadwan N. 54Haftmann C. 45Hagau N. 63Hakim H. 61Hammer A. 15Hammoudeh M. 54Hanly J.G. 59Harin A. 23Haringer B. 21Haroche J. 50Harris Altice A. 36Hartvig N. 42Hassanien M. 40Haya A. 35Heegaard N. 60Heegaard N.H. 57Hennessy B. 51Herlitz Lindberg M. 19, 57Hermansen M. 56Herraiz I. 36Herrero J.C. 54Hervás Marín D. 44, 45, 48, 55Hewins P. 10Hie M. 50Hiepe F. 9, 14, 15, 23, 41, 45, 49Hjelmborg J. 56Holloway D. 14Hong S. 43, 47, 52, 57Hong Y.S. 61Horcada L. 27Horita T. 34Horne H. 15Hotea I. 63Hough D.R. 49Houssen M. 42Houssiau F. 15, 26, 34Hoxa A. 39Hoxha A. 28, 33Hoyer B. 9Hoyer B.F. 23Hrncir Z. 43Hughes G. 8Huizinga R. 16Humrich J. 15, 45Humrich J.Y. 12, 45Hunt D. 25Hussien Y.S. 42Hutanu A. 63Huynh-Do U. 26, 42, 47

IIaccarino L. 9, 12, 14, 16, 18, 29, 37, 64Iglesias A. 46Ilisson J. 55Illei G. 9, 52Inanc M. 26, 56Inês L. 26, 32, 50, 53Ingegnoli F. 21

Interlandi G. 62Iordache C. 37Iori E. 41Irwin S. 42Isenberg D. 12, 21, 34, 50Iseppon A. 21Ismail N.M. 42Iuliano A. 60Iversen L.V. 60Ivorra Cortés J. 40, 44, 45, 48, 55Izmirly P. 34

JJabado O. 46Jackson A. 25Jacob C. 50Jacobs B. 21, 43Jacobsen S. 11, 20, 38, 44, 56, 57, 60Jakobi K. 36Jakobsson P.J. 44Jara L.J. 30Jawad A.S.M. 45Jayne D. 12, 19Jensen M. 17Jensen-Urstad K. 19, 57Jesus D. 22, 26, 50Jiménez I. 54Jin Z. 17Jolly M. 34, 59, 60Jonkman M.F. 35Joo Y. 49Jordan N. 25Jung J. 47, 57Jun J. 59Jury A. 25Juste A.M. 42

KKabouraki E. 59Kabrani E. 41Kachakova D. 45Kacso I. 63Kalden J. 13Kalinou C. 54Kalla A. 54Kallenberg C. 21Kalunian K. 9Kalunian K.C. 49Kamali S. 26, 56Kambas K. 20Kamphuis S.S.M. 24Kaneva R. 45Kang J. 52Kansal S. 14Kapsia E. 50Karageorgas T. 13Karatas A. 48Karmali R. 55Karolak I. 59Karolia S. 53Kastirr I. 21

Katagis G. 48, 55, 58, 60, 63Kataoka H. 49Kato M. 34Katsavouni C. 50, 54Katsibri P. 13Katsimbri P. 42Kay S. 56Kelly S. 46Kerboua K. 53Khamashta M. 9, 33, 38Khodadadi L. 9Kim H. 59Kim J. 52Kim J.M. 63Kim J.N. 52Kim S. 43, 47, 57Kim S.H. 63Kim S.K. 52Kim Y. 52Kivitz A. 49Kjær Winberg L. 38Kloke L. 12Klotsche J. 23Kobayashi Y. 21Koca S. 48Koch K. 60Kolarov Z. 45Kolovou K. 50Kondo M. 49Kontos F. 42Korczak-Kowalska G. 44Koren O. 10Korish S. 49Kostoglou-Athanassiou I. 50, 54Kotsogianni C. 42Kousios A. 47Kozakowski N. 43Kribben A. 26Kriki P. 50Kuehl A. 12Kuhn A. 31Kulcsár A. 42Küppers L. 39Kuzenko A. 28Kyogoku C. 49Kyriacou K. 47

LLabrador Sánchez E. 40, 44, 45, 48, 55Lambers W. 35Lambert N.C. 48Lambrechtsen J. 56Lannfelt K. 52Lanzani C. 45Lanzone A. 39Lara Mejía A. 30Larghi P. 21Lari S.A. 27Larosa M. 16, 18, 29, 39Larsson A. 19, 36, 46Latini A. 17, 44

83

Lauwerys B. 47Lazzaroni M. 30, 39Leccese I. 18, 26, 52Lee C. 52Lee C.W. 52Lee D. 14Lee E. 49Lee J. 52Lee K. 52Lee S. 43, 47, 52, 57Legerton C. 49Le Guern V. 30, 34Leiss H. 21, 43Lengqvist J. 44Leon M.J. 44Lerstrom K. 62Le Thi Huong D. 30Leye A. 61Li M. 24, 32, 35, 37, 60Li Y. 24Lichauco J. 63Lightstone L. 34, 36Lim D. 52Limonta M. 29Lindhardsen J. 56Lindholt J. 56Liossis S.N. 9Liu A. 21Lladó A. 49Logan S. 10Lois-Iglesias A. 24, 27Lojacono A. 39Lopes M.J.P. 51López-Hoyos M. 35, 39, 56Lopez Jimenez E.A. 36López-Longo F.J. 24, 27, 56López-Paz J.L. 41, 42Lorenzi H. 46Lourenço F. 51Lucente L.N. 52Lúcio I. 54Luisetto R. 12, 14, 38, 41, 64Lundberg I. 44Lupoli F. 39Lutea M. 55Ly F. 61

MMaccarrone M. 48Machairas P. 50Machaly S. 42Maestroni S. 40Magnani O. 55Mahler M. 33, 42Maier A. 30Makan K. 22Makol A. 17Malavolta N. 30Maldonado M. 46Malmström V. 19Mamoulaki M. 59

Manfredi A.A. 20, 28, 45, 53Maniu A. 63Manjarez-Orduno N. 14Man M. 63Manoustathopoulou S. 25Mansouri H. 61Mansutti E. 41Manunta P. 45Manzi S. 31, 36Maquieira A. 41Marañón C. 54Marcor P. 33Margiotta D.P.E. 48Mariette X. 9, 12Marinaki S. 50Marinescu C. 64Marino G. 10, 11, 19, 28Marquart K. 13Martin G.V. 48Martin T. 48Martinez A. 16Martínez Cordellat I. 40, 44, 45, 48, 55Martínez-Taboada V. 27, 35, 39, 56Martins da Silva B. 13, 53Mashreghi F. 45Massaro L. 12, 14, 18, 26, 31, 52, 59Masseau A. 30Masters S. 23Mathian A. 50Mathieu A. 22, 31, 59Mattia E. 33Maugeri N. 20Mauri C. 14Mavragani C. 61Maxim R. 37, 53, 57Mayer M. 60Mazzoni D. 37McGlasson S. 25Mejia M.C. 63Melero R. 27Menard L. 14Mendonca D. 13, 52, 53Mendoza Pinto C. 61Meneghel L. 33Menezes M. 55Menn-Josephy H. 34Meroni M. 29, 30, 40Meroni P.L. 14, 21, 27, 28, 30, 33, 48, 63Merrill J.T. 9, 15, 26, 46Messa P. 55Messuti L. 11, 19Metallo C. 24Mickley H. 56Midgley A. 41, 42, 53Mihailescu T. 54Miklós K. 42Min J.K. 61Minisola G. 30, 60Miranda F. 11, 18, 20, 31, 37Miranda-Hernández D. 30

Mitsis C. 48, 58, 60Mobarrez F. 46Mociran A. 46Moder K. 17, 47Mohammed A. 58Mohan C. 46, 48Moiola L. 53Mok C. 49, 57Monova D. 47, 54Monov S. 45, 47, 54Monserrat Sanz J. 44Montanucci P. 12Montecucco C. 30, 40Montilla C. 27Monzó I. 41, 42Moon S.J. 61Moraes-Fontes M.F. 49, 51, 54Morais S. 41, 42Morand E. 8, 9, 18Morel N. 30Morell Hita M. 21Morelli F. 52Morello F. 12, 14, 18, 31Moresi S. 39Morissens M. 55Moro M. 21Moroni G. 9, 19, 55Moruno H. 44Mosad E. 42Mosca M. 18, 22, 30, 31, 50, 59Moscarelli E. 31Mosheta E. 48, 55, 58, 60, 63Motta F. 40Mouriño C. 24, 27Moutsopoulos H.M. 16, 61Movasat A. 44Mozetic P. 48Mplanas A. 41Mucha K. 44Muiesan M.L. 57Mujeeb I. 54Mukai M. 49Muñoz C.H. 47Muñoz P. 35, 39, 56Muntean L. 64Murdaca G. 55Muresanu D. 54Murphy E. 59Mvudi A. 22Mvudi A.N. 42

NNadler S. 14Nájera Herranz C. 40, 48, 55Nallasivan S. 63Nalli C. 33, 59Nalotto L. 16, 18, 29, 54Nash P. 46Natalucci F. 31, 59Navarini L. 48Navarra S. 27, 34

84

Navarro E. 46Navarro R. 46Ndiaye Diop M.T. 61Ndongo S. 61Nechita Ferreira M. 55Negrini S. 55Negueroles Albuixech R. 40, 44, 45, 48, 55Neroutsos E. 50Neseem N. 42Neuman H. 10Neydani Tarakmeh H. 45Ngandu-Ntumba H. 22Ngandu Ntumba M.H. 42Nicolaides K. 29Nicolaou O. 47Niederreiter B. 21, 43Nielsen C.H. 38Nielsen C.T. 57, 60Niewold T. 17Niewold T.B. 43Nika A. 59, 60Nikolaou C. 43Norman G.L. 33Novelli G. 17, 44Novelli L. 35Nowik M. 19

OOcal L. 26, 56Odhams C. 17Odhiambo J. 62Öhrvik J. 19Okamba P. 62Oke V. 36Oku K. 34Olave V. 46Olivares González L. 44, 45Olivé A. 24, 27, 56Oliveira J. 63, 64Oliveira S. 63Olivieri I. 30Oller Rodríguez J.E. 40Omercikoglu Z. 48Ometto F. 16Omondi E. 62Omran E.A.H. 42Omran N. 62Orefice V. 18Orquevaux P. 30Ortego N. 16Orteu C. 49Ortiz Reyes B. 47Ortiz Sanjuán F.M. 40, 44, 45, 48, 55Ortolan A. 54Osborn T. 17Ossipova E. 44Ostensen M. 30Østergaard O. 60Otieno F. 62Otón T. 27Oyoo G. 62Ozulu B. 59

PPacheco L. 46Pacucci V. 11, 18, 37Paczek L. 44Padjen I. 60Padoan R. 54Padovan M. 30, 64Paglionico A. 10, 11, 19, 28Paini A. 57Pakozdi A. 39Palazzo L. 57Pamfil C. 40, 43, 46, 50, 54, 63, 64Panarra A. 49, 51, 54Panousis N. 43Paolazzi G. 30, 62Papadopoulos A. 42Papadopoulou A. 48, 55, 58, 60, 63Papageorgiou L. 48, 60, 63Park D. 52Park K. 59Parker B. 61Parodi A. 31Parodis I. 19, 46, 48Paroni M. 21Parvu M. 53Patsouras M. 33Paule L. 44Pavlidis P. 43Pazzola G. 30Peak M. 41, 42, 53Peccatori S. 30Pego-Reigosa J.M. 24, 27, 56Pehlivan O. 56Pellecchio M. 55Penatti A. 21Pendolino M. 18, 31Peneva E. 54Pengo V. 28, 33Pennaforte J.L. 30Pennoni I. 12Penza E. 55Pereira S. 64Pereira da Silva J.A. 32, 53Peretz A.S. 57Perez Gómez A. 44Perkowska-Ptasinska A. 44Perreau M. 41Perricone C. 17, 18, 21, 26, 31, 37, 44, 52, 59Perricone R. 11, 30, 35Pescara T. 12Petcu A. 54Peters J. 45Petricca L. 10, 11, 19, 28Petri M. 24, 27, 34Pettersson S. 19Pha M. 50Piantoni S. 23, 57Piette J.C. 30, 34, 57Piga M. 31, 59Pignataro L. 21Pilely K. 44

Pillay L. 60Pineau C. 34Piñeros L.G. 63Pinheiro S. 51, 58, 63, 64Pinto P. 41Pirone C. 61Pisati M. 63Pisetsky D. 46Pluma A. 39Pobiner B. 15Politi C. 17, 44Pombo L.M. 63Pomirleanu C. 37, 53, 57Pompieri A. 59Pons-Estel B. 22, 27, 47Pontisso P. 14, 64Popov H.I. 46Porta S. 16Portilla V. 56Pouget-Abadie J.F. 57Poulsen M.K. 56Pournou A. 48, 55, 58, 60, 63Poveda Marín G. 40, 48, 55Prevete I. 30, 60Preziosa P. 53Pruunsild C. 55Puchades R. 41, 42Puchner A. 21, 43Punzi L. 12, 14, 27, 41Puppo F. 50, 55Putterman C. 36Pyne D. 39, 45

QQian J. 24, 60Qi W. 24Quaglini S. 55Quartuccio L. 41, 51Quevedo V. 24

RRadbruch A. 9, 12, 15, 23, 41, 45Radice A. 48, 55Raffiotta F. 55Raine R. 54Rajakariar R. 39, 45Ramazzotto F. 39Ramires T. 54Ramirez G.A. 20, 28, 45, 53Ramoni V. 29, 30, 40Rampello S. 40Rashkov R. 45Rasmussen N. 57Ravindran Y. 63Rednic S. 40, 46, 50, 54, 63, 64Reggia R. 14, 30, 39Rengers P. 13Repa A. 59Restrepo M. 47Reyes S. 63Rhodes B. 23Riancho-Zarrabeitia L. 35, 39, 56

85

Ribeiro R. 29, 55, 58Ribi C. 26, 42, 47Richter J.G. 50Rico E. 46Ricois S. 62Riedel R. 45Riemekasten G. 12, 15, 45Rifkin I. 34Riga J.P. 54Ríos R. 16Riso N. 51Ritis K. 20Rizzo A. 11Rocca M.A. 53Roccatello D. 23Rocha G. 64Rodrigo R. 44, 45Rodrigues M. 22, 26, 30, 33, 50, 64Rodriguez Almaraz E. 36Roggenbuck D. 33, 48Román Ivorra J.A. 40, 41, 42, 44, 45, 48, 55Romano M. 40Romeo N. 30Rönnblom L. 34, 51Roozendaal C. 35Rosa S. 28Rose A. 12, 15Rossi M.T. 64Roudier J. 48Rovere P. 39Rovere-Querini P. 20, 28, 45, 53Rozenberg F. 50Rúa-Figueroa I. 24, 27, 56Rubio B. 62Ruffatti A. 28, 29, 30, 33, 39, 58Rufini S. 17, 44Ruiz E. 27Ruiz L. 44Ruiz-Irastorza G. 16, 25, 34

SSaavedra M.A. 30Sabbadini M.G. 20, 45, 53Saccon F. 14, 18, 38Safer P. 36Safran A. 41Sahin K. 48Sahinkaya Y. 56Sallam M. 42Sall N.D. 61Salvador L. 27Salvan E. 33Salvarani C. 30Salvetti M. 57Salvi S. 39Salzberger W. 43Sánchez A. 27, 30Sanchez Atrio A.I. 44Sanchez-Piedra C. 56Sander O. 39

Sand N.P. 56Sangalli F. 53Sangle S. 25Sanz I. 44Saracini S. 48Saracino A. 49Sargin G. 47Sarzi-Puttini P. 32, 55Satchell S.C. 53Sauer G.M. 50Sauvanet A. 57Savey L. 57Scarsi M. 23Schafer P. 49Scheinberg M. 78Schiavon F. 54Schierack P. 33Schirmbeck L. 42Schneider M. 8, 13, 18, 24, 36, 39, 50Schulz-Knappe P. 13, 36Schwarting A. 11, 15Sciandrone M. 52Sciascia S. 28Sciatti E. 57Sciorati C. 45Scirè C.A. 59Scrimin F. 40Sebastiani G.D. 30, 35, 60Sebbar H. 39Seemayer C. 51Selmi C.F. 27, 30Senturk T. 47Sequeira W. 59, 60Seretis A. 43Sfichi M. 63Sfikakis P. 50Shahin D. 42Shiruli B. 62Shoenfeld Y. 8, 10, 21, 33, 34, 64Shukla P. 34Shumnalieva R. 45Shvets T. 43Sidiropoulos P. 13, 41, 43, 59Siegert E. 15Sifuentes Giraldo W. 25Silva M. 51, 58, 63, 64Silvagni E. 64Simon J. 42Simon K. 23Simon S.P. 63Sinico R.A. 19, 55Sinigaglia L. 30Sjöwall C. 43, 57Skalioti C. 50Smerla R. 61Smolen J. 15, 21, 43Snyder M. 47So A. 41Sogni P. 57Sokratous K. 47Solomons N. 16Son C. 63

Sorek R. 36Sorice M. 11Soukup T. 43Sousa G. 55Sousa J.G. 55Sousa M.J. 29, 55Sousa Ines L. 22Specker C. 39Spinelli F.R. 11, 12, 14, 17, 18, 20, 26, 31, 37, 44, 52, 59Spyrou G. 13, 59Stagnaro C. 18, 50Stassaldi D. 57Staveri C. 9Steffesen F.H. 56Steiner C.W. 21, 43Stetsko D. 14Stevanovic R. 60Stohl W. 15Stolzel K. 21Stummvoll G.H. 21, 43, 52Suchard S. 14Suh C. 43, 47, 57Sundelin Von Feilitzen B. 19, 52Sundström M. 44Sundström Y. 44Sun J. 21Svenungsson E. 19, 36, 39, 46, 57Syngelaki A. 29Szabo I. 46, 54Szabó Z. 42

TTabacco S. 39Taddei S. 22Taddeo A. 9, 23, 41Tamas M.M. 46Tanassi J.T. 60Tanha N. 44Tani C. 18, 22, 30, 32, 50Taraborelli M. 57, 60, 62, 64Tarakmeh H. 39Tatsina I. 48, 55, 58, 60, 63Taulaigo A. 49Taunton J. 44Teheran A. 63Tejero R. 41, 42Tektonidou M. 19, 40, 43Templin L. 45Teng Y.K.O. 24Terlizzi V. 57Tesch S. 45Tian Z. 24Tikly M. 22, 42, 53, 60Tilinca M. 53Tincani A. 8, 14, 23, 26, 28, 30, 33, 34, 36, 39, 42, 57, 59, 60, 62, 64, 78Todesco S. 31Todorova M. 47, 54Tolusso B. 10, 11Tomietto P. 59

86

Toms J. 43Tonello M. 33, 58Tonutti E. 40Toro-Dominguez D. 23Torp-Pedersen C. 56Torretta S. 21Tosounidou S. 13Tóthné Fischer L. 42Toubi E. 23, 38Townsend R. 46Trachana M. 43Trendelenburg M. 26, 42, 47Trevisani M. 30Trezzi B. 55Triggianese P. 35Triolo G. 11Truglia S. 11, 18, 20, 31, 37Truszewska A. 44Tsifetaki N. 48, 55, 58, 60, 63Tsokos G. 21Tulbure D. 40Tzanakakis M. 59Tzanakis I. 59Tzanavari A. 50, 54Tzioufas A. 33

UUbiali T. 14Ucar Angulo E. 39Ugarte A. 16Uña J. 27Urowitz M. 9, 18, 22, 32, 62Urrego T. 47Usategui A. 36

VVacchi L. 53Vaclavkova A. 51Vadacca M. 30Vagelli R. 18, 22, 50Vaglio Tessitore I. 28Vagnani S. 18, 50Valeri C. 35Valero Sanz J.L. 40, 44, 45, 48, 55Valesini G. 11, 12, 14, 17, 18, 20, 25, 26, 31, 37, 44, 52, 59Vallejo P. 36Valsami G. 50Van Den Houte K. 54van Dijk W. 24Vanegas A.L. 47Van Vollenhoven R. 15, 18Varela Hernández N. 21Varriano V. 10, 11, 19, 28Vasconcelos C. 13, 34, 37, 52, 53Vasques M. 49Vásquez G. 47Vautier-Brouzes D. 30Vegas-Revenga N. 56Velcherean-Nicola M. 64Vele P. 63

Venter J.A. 54Venturini S. 40Verbeet T. 55Verginis P. 20, 41, 43Vicente M. 49Vidal C. 51Videira T. 41Vieira L. 54Vikerfors A. 46Visalli E. 30Vitolo B. 40Vivaldelli E. 30Vizzardi E. 57Vlachoyiannopoulos P. 33, 50Voidazan S. 53Vokurkova D. 43Volkov A. 10Voll R. 14, 23Volpe A. 62Volpe C. 40Vomero M. 11Von Spee-Mayer C. 12, 15Vordenbäumen S. 13, 36Voss A. 56Vsetecka D. 17Vyse T. 17, 23, 44

WWallace D.J. 15Wallace S. 36Wallén H. 46Wang L. 9, 52Wang Q. 24Wang Y. 32, 60Wang Z. 32Watkins A. 34Wechsler B. 30Wegener W.A. 15Weiswasser M. 49Wei W. 24Wen L. 52Werth V.P. 9, 49Westhovens R. 46Westra J. 35Wilhelm T. 41Willers R. 50Wilson G. 34Winkler-Rohlfing B. 50Winter O. 41Wirkowska A. 44Wissing K.M. 54Won S. 49Woo J. 43Wright H.L. 41Wright R.D. 41, 42, 47, 53Wu K. 12

XXavier Pires S. 57Xavier Pires S.I. 57

YYahya R. 16Yasuda K. 34Yasuda S. 34Yavuz S. 59Yazici A. 59Yee C.S. 13Ye S. 24Yilmaz Y. 59Yim S. 59Yim Y. 52Yoo B. 52Yoo S. 9Yssel H. 50Yuce T. 56

ZZagato L. 45Zampoulaki A. 43Zanatta E. 58Zandman-Goddard G. 46Zandonà L. 40Zani R. 57Zanola A. 23, 42Zatti S. 39Zdrenghea D. 50Zea Mendoza A. 25Zen M. 14, 16, 18, 29, 53, 59Zeng X. 24, 27, 32, 60Zervou M.I. 43Zhang C. 14Zhang M. 24Zhang W. 24Zhang X. 24Zhang Z. 24Zhao J. 24Zheng Y. 24Zhu P. 24Zickert A. 19, 36, 46, 48, 52Zirkzee E.J. 24Zotos N. 48, 55, 58, 60, 63Zucht H.D. 13, 36Zufferey P. 41Zuin M. 27Zuliani F. 41, 51Zuliani L. 30Zuo X. 24

PLATINUM SPONSOR

GOLD SPONSOR

SILVER SPONSORASTRAZENECA

SUPPORTERSF. HOFFMANN LA ROCHE LTD

INOVA DIAGNOSTICS

JANSSEN CILAG

MEDIPAN

MUNDIPHARMA

UCB PHARMA

ACKNOWLEDGEMENTS

Documents

10 - sleuro.org · SYMPOSIUM 13.30-14.30 14.30-16.15 SLE and clinical trials: past and future Traditional synthetic drugs in SLE SLE genetics 16.15-16.45 16.45-18.30 Targets in SLE